采用每日一次白消安注射液预处理方案的异基因造血干细胞移植及造血干细胞移植治疗非恶性疾病的临床研究
|
摘要
目的为了提高预处理方案的抗肿瘤效应,我们探讨含每日一次白消安注射液(ⅣBu)预处理方案进行异基因造血干细胞移植(allo-HSCT)的疗效和毒副作用。方法对27例患者(其中25例为恶性血液病,2例为肾上腺脑白质营养不良)分别采用了含每日一次ⅣBu的改良白消安/环磷酰胺(Bu/Cy)、改良Bu/Cy+猪抗人胸腺淋巴细胞球蛋白(ATG)和氟达拉滨(Flu)/白消安+猪ATG预处理方案进行了allo-HSCT,患者的中位年龄是31岁(3岁～61岁),其中亲缘人类白细胞抗原(HLA)全合移植19例,亲缘HLA不合移植4例,非亲缘成人供者移植3例,非亲缘脐带血移植1例。在预处理过程中使用ⅣBu每日剂量为3.2mg.kg-1.d-1,每日剂量稀释至原溶液体积的10倍,使用输液泵一次注射完毕,输注时间维持4小时,在使用ⅣBu过程中采集开始使用后2h、3.9h、6h、8h、12h、16h、22h七个时间点的血样,采用液相色谱的方法检测了白消安注射液在各个时间点的血药浓度,并记录预处理相关毒性、移植后并发症发生的情况及生存和原发病状况。结果中位随访了8个月(0.3月～18月)。中位白消安清除浓度是0.241L/h/kg,平均每日曲线下面积是13877.5ug/L·h。除1例在移植后第10天死于脑出血,干细胞未植入外,余患者在移植后30天行短串联重复序列(STR-PCR)检测,除1例肾上腺脑白质营养不良患者行非亲缘脐带血移植未植入外,其余患者均显示为完全供者的基因型。移植过程中3例患者出现轻度口腔粘膜炎,11例患者出现轻度胃肠道反应,7例患者出现肝功能异常(其中6例为可逆的轻度异常,1例为重度黄疸),6例发生出血性膀胱炎,但均为迟发性,无1例发生癫痫和肝静脉闭塞病(VOD)。在可评价的患者中,急性移植物抗宿主病(aGVHD)的发生率为64.0%(16/25),其中Ⅲ～Ⅳ度的aGVHD仅为28.0%(7/25),慢性移植物抗宿主病(cGVHD)的发生率为77.0%(17/22),其中广泛型为41.0%(9/22)。结论每日一次ⅣBu预处理方案进行allo-HSCT血药浓度稳定,使用方便,安全有效,临床耐受性好,毒性并未增加,克服了口服白消安生物利用度低和难以确保准确剂量的不足。
目的探讨异基因造血干细胞移植(allo-HSCT)治疗重型再生障碍性贫血(SAA)的方法和疗效。方法对30例SAA的患者进行了allo-HSCT。男18例,女12例,中位年龄25岁(3岁～48岁)。其中非血缘脐带血移植2例,非血缘成人供者移植4例,人类白细胞抗原(HLA)相合的亲缘移植19例,HLA一个位点不合的亲缘移植5例,其中3例患者采用环磷酰胺(200mg/kg)+猪抗人胸腺淋巴细胞球蛋白(100mg/kg)的非清髓性预处理,余患者均采用环磷酰胺(100-120mg/kg)+氟达拉宾(150mg/m2)+猪抗人胸腺淋巴细胞球蛋白(100mg/kg)。其中15例采用的是粒细胞集落刺激因子动员的骨髓联合外周血干细胞移植,10例采用粒细胞集落刺激因子动员的外周血干细胞移植,3例采用的是粒细胞集落刺激因子动员的骨髓,2例采用的是双份非血缘脐带血输注。预防移植物抗宿主病(GVHD)在HLA全合的亲缘移植采用环胞菌素A(CsA)联合短疗程甲氨蝶呤(MTX)的方案,对于HLA不合的亲缘移植和非血缘成人供者移植移植在CsA联合短疗程MTX的方案基础上加用霉酚酸酯(MMF)的方案,对于非血缘脐带血移植采用CsA联合霉酚酸酯(MMF)的方案。结果除3例患者在移植期间死亡外(1例脐带血移植患者在移植后18天死于感染,1例在移植后9天死于死于感染性休克,1例在移植后8天死于重度肝静脉闭塞病引起的多器官功能衰竭),1例患者血小板未植活,后再次输注供者外周血干细胞后获得植活外,余患者移植后造血恢复顺利,于中位+12天(+6～+21天)WBC植入,+15天(+9～+30天)PLT植入,除1例脐带血移植患者移植物未植入,自身恢复外,余患者+30天行患者骨髓STR-PCR检测显示为完全供者的基因型,中位随访了25.6月(0.3月～84月),所有患者的总生存率(OS)是83.3%。在可评价的患者中,急性移植物抗宿主病(aGVHD)的发生率为11.1%(3/27),其中Ⅲ的aGVHD仅为1例,慢性移植物抗宿主病(cGVHD)的发生率为21.7%(5/23),其中广泛型为8.7%(2/23)。结论异基因造血干细胞移植是治疗重型再生障碍性贫血的有效方法,但非脐带血干细胞植入不理想,需谨慎,亲缘HLA全合的移植与HLA一个位点不合的移植在干细胞植入和总生存率方面无差异,亲缘移植患者在使用骨髓联合外周血干细胞移植还是单用外周血干细胞移植两者在干细胞植入方面亦无差异。非血缘成人供者移植的晚期排斥率增加,尚需优化预处理方案以防止晚期植入失败。
目的探讨自体外周血干细胞移植(APBSCT)联合免疫抑制剂治疗自身免疫性疾病(AID)的初步疗效。方法对17例AID患者进行APBSCT同时联合或不联合使用猪抗胸腺淋巴细胞球蛋白(ATG)或利妥昔单抗体内净化。其中16例患者为系统性红斑狼疮,1例为重叠综合征(系统性红斑狼疮合并系统性硬化症),1例为自身免疫性溶血性贫血。17例均采用环磷酰胺(CTX) 4g/m2化疗联合粒细胞集落刺激因子(G-CSF) 5μg/kg/d动员患者的外周血干细胞,14例患者予CTX 50mg/kg/d×4d预处理后回输保存的外周血干细胞,1例患者予BEAM方案预处理后回输保存的外周血干细胞,回输前予ATG(猪)20mg/kg/d×2d,回输后予ATG(猪)20mg/kg/d×2d行体内净化。1例在预处理中出现真菌性败血症而仅使用CTX 50mg/kg/d×4d预处理,未使用ATG行体内净化,1例自身免疫性溶血性贫血患者未使用ATG,而是分别于移植后+1d及+8d予抗利妥昔单抗600mg/d (375mg/m2)行体内净化。回输中位单个核细胞(MNC)大于5.0×108/kg,中位CD34+细胞大于2.0×106/kg,移植后口服泼尼松5～10 mg/d或霉酚酸酯(MMF) 0.5g/d维持治疗。结果17例患者移植后造血均恢复顺利,中性粒细胞绝对计数(ANC)于中位时间+9d(+8d～+11d)植活,血小板于于中位时间+12d(+9d～+15d)。干细胞动员过程中有5例患者出现疾病活动,加用泼尼松后控制。1例自身免疫性溶血性贫血患者在移植后网织红细胞降至正常,胆红素恢复正常,未再发生溶血表现。移植后5月Coomb's试验转阴,所有结缔组织病患者均于移植后1个月左右皮疹及关节疼痛逐渐消失,SIEDAI降至5分以下,尿蛋白减少或消失。移植后3月复查自身抗体滴度下降。所有患者中位随访至移植后42.6个月,5例患者死亡,均为系统性红斑狼疮的患者,3例复发,亦为系统性红斑狼疮,余患者造血功能恢复良好,病情处于持续缓解状态。结论APBSCT是治疗自身免疫性疾病的有效方法之一,要严格掌握适应症,要注意在移植过程中有感染和疾病活动的可能,移植后要注意致命性间质性肺炎的发生。
目的探讨异基因造血干细胞移植治疗X连锁的肾上腺脑白质营养不良(X-ALD)的方法和可行性。方法对2例已经有神经系统症状的X-ALD的患者进行了异基因造血干细胞移植。均采用氟达拉宾(150mg/m2)+白消安注射液(9.6mg/kg)+猪抗人胸腺淋巴细胞球蛋白(100mg/kg)的非清髓性预处理后,1例患者回输了非血缘双份脐带血,另1例患者回输父亲HLA 5/6相合的经粒细胞集落刺激因子(G-CSF)动员的外周血干细胞。非血缘脐带血移植预防移植物抗宿主病(GVHD)采用环胞菌素A(CsA)联合霉酚酸酯(MMF)的方案,亲缘父亲HLA 5/6相合的移植GVHD采用CsA联合短疗程甲氨蝶呤(MTX)的基础上加用霉酚酸酯(MMF)的方案。结果两例患者移植后造血恢复顺利,但行非血缘脐带血移植患者短串联重复序列(STR-PCR)检测显示为脐带血未植入,亲缘父亲HLA 5/6相合的移植获得供者的完全嵌合体,行脐带血移植患者白细胞自行恢复,血小板在回输备用的自体外周血干细胞后恢复。脐带血移植患者无移植物抗宿主病(GVHD)表现,在移植过程中神经系统病变有加重。另一例接受父亲HLA 5/6相合移植的患者发生Ⅱ度的急性GVHD,Ⅲ级的病毒性出血性膀胱炎,巨细胞病毒血症,均经治疗后好转,但卧床时间较长,活动能力下降,早期测长链脂肪酸较移植前有所下降。结论本中心经验结合文献复习认为异基因造血干细胞移植是一种可行的治疗X-ALD的有效方法,但对早期神经系统症状不明显的患者疗效较好,在移植过程中患者的神经系统损伤可能会加重,且移植的疗效尚需长期观察。
Objective To improve the conditioning regimen of anti-tumor effect, we explore the of efficacy and toxicity with once-daily intravenous busulfan (IV Bu)-based conditioning regimen for allogeneic hematopoietic stem cell transplantation (allo-HSCT). Methods Of 27 patients (25 cases with hematologic malignancies and 2 cases with adrenoleukodystrophy) were used once-dailyⅣBu with the improvement of busulfan/ cyclophosphamide (Bu/Cy), improvement of Bu/Cy + Pig anti-human thymocyte globulin (ATG) and fludarabine (Flu)/busulfan+ pig ATG conditioning regimens for allo-HSCT.The median age of patients was 31 years (3 years to 61 years). In which genetic human leukocyte antigen (HLA) full matched transplantation in 19 cases, relatives of HLA mismatched-transplantation in 4 cases, unrelated adult donor transplantation in 3 cases, unrelated cord blood transplantation in 1 case. Used in the pretreatment dose of IV Bu daily 3.2mg.kg-1.d-1, the daily dose was diluted to 10 times the original solution volume, the use of infusion pump completed the first injection, infusion time for 4 hours. Collected blood samples from using the IV Bu process started after the 2h,3.9h,6h,8h,12h,16h,22h in seven time points, the use of liquid chromatography to detect the intravenous busulfan at various time points blood concentration, and record related toxicity, the case of complications after transplantation,and survival and the primary disease condition.
Results Median follow-up of 8 months (0.3 months to 18 months). The median concentration of busulfan clearance 0.067ml/min/kg, the average daily area under the curve is 13877.5ug/L*h. After transplantation 1 patient died of cerebral hemorrhage in 10 days, stem cells are not implanted, the more than 30 days after transplantation in patients with short tandem repeat lines (STR-PCR) test, only 1 case with adrenoleukodystrophy patients received cord blood transplantation is not implanted, the remaining patients showed complete donor for the genotypes.3 patients had mild mucositis,11 patients had mild gastrointestinal reactions,7 patients had abnormal liver function (including 6 cases of mild reversible abnormalities in 1 case severe jaundice),6 cases of hemorrhagic cystitis, but were delayed and no one case occured epilepsy and hepatic veno-occlusive disease (VOD). In the evaluable patients, incidence of acute graft-versus-host disease (aGVHD) was 64.0% (16/25), in which the degree of aGVHDⅢ～Ⅳonly in 28.0%(7/25), the incidence of chronic graft-versus-host Disease (cGVHD) 77.0%(17/22), the extensive type was 41.0% (9/22). Conclusions Once-daily IV Bu allo-HSCT conditioning regimen has good plasma stability, easy to use, safe and effective, and good clinical tolerance, toxicity did not increase to overcome the oral busulfan bioavailability is low and difficult to ensure accurate dosage.
Objective To explore the method and effect of allogeneic hematopoietic stem cell transplantation (allo-HSCT) for patients with severe aplastic anemia (SAA). Methods 30 cases with SAA patients received allo-HSCT.18 males and 12 females, median age 25 years (3 years to 48 years). Including 2 cases reveived unrelated cord blood transplantation, unrelated adult donor transplantation in 4 cases, human leukocyte antigen (HLA) matched transplantation in 19 cases, HLA one locus incompatible transplants in 5 cases,3 patients were treated with cyclophosphamide (200mg/kg)+ pig anti-human thymocyte globulin (100mg/kg) of non-myeloablative conditioning, the other patients were treated with cyclophosphamide (100～120mg/kg)+Fludarabine (150mg/m2)+pig anti-human thymocyte globulin (100mg/kg). Among them,15 cases were reveived the granulocyte colony stimulating factor to mobilize bone marrow combined peripheral blood stem cell transplantation,10 patients reveived granulocyte colony stimulating factor mobilized peripheral blood stem cell transplantation,3 cases reveived bone marrow of granulocyte colony stimulating factor mobilization,2 cases received double unrelated umbilical cord blood infusion. Prevention of graft versus host disease (GVHD) in the matched relatives of HLA transplantation with cyclosporine A (CsA) combined short course methotrexate (MTX) program, the affinity for the HLA one locus mismatched transplants and unrelated donor transplantation received CsA combined transplantation program short course MTX based on the use of mycophenolate mofetil (MMF) program, for unrelated cord blood transplantation mycophenolate mofetil combined with CsA (MMF) program. Results In addition 3 patients died during the transplant outside (n=1 cord blood transplant patients died of infection 18 days after transplantation,1 patient died 9 days after transplantation died of septic shock,1 patient died 8 days after transplantation and severe hepatic veno-occlusive disease caused and multiple organ failure),1 patient without platelet engraftment, again obtained engraftment after the infusion of donor peripheral blood stem cells, the hematopoietic recovery after transplantation in patients over the smooth, the median day+12 (+6 To+21 days) WBC implantation,+15 days (+9 to+30 days) PLT implantation in patients with cord blood transplantation in 1 patient without graft implantation, self-recovery, the other patients were+30 days STR-PCR analysis showed that bone marrow is completely donor genotype, with a median follow-up of 25.6 months (0.3 months to 84 months), overall survival for all patients (OS) was 83.3%. In the evaluable patients, the incidence of acute graft-versus-host disease (aGVHD) was 11.1%(3 /27), in which only 1 occurredⅢgrade aGVHD, incidence of chronic graft versus host disease (cGVHD) was 21.7%(5/23), which extensive type was 8.7%(2/23).
Conclusions Allogeneic hematopoietic stem cell transplantation is the effective treatment for severe aplastic anemia, but cord blood stem cells will need to be cautious, HLA matched patients and one locus mismatched patients of implantation of stem cell transplantation and overall survival was no difference, in the use of bone marrow transplant patients peripheral blood stem cell transplantation in the joint or single peripheral blood stem cell transplantation with stem cells both in terms of implantation has no difference. Unrelated donor transplantation in adults with advanced rejection rate increases, still need to optimize the conditioning regimen to prevent late implant failure.
Objective To explore the efficacy of autologous peripheral blood stem cell transplantation (APBSCT) combined immunosuppressive for autoimmune diseases (AID).
Methods AID patients in 17 cases received APBSCT also use the pig with or without antithymocyte globulin (ATG) or rituximab in vivo purging. Of these,16 patients were systemic lupus erythematosus,1 case with overlap syndrome (systemic sclerosis systemic and lupus erythematosus),1 case of autoimmune hemolytic anemia.17 patients were using cyclophosphamide (CTX) 4g/m2 chemotherapy and granulocyte colony stimulating factor (G-CSF) 5μg/kg/d mobilized peripheral blood stem cells in patients,14 patients received tCTX 50mg/kg/d×4d before reinfusion of peripheral blood stem cell preservation, and 1 patient received the BEAM conditioning. Before pretreatment transfusion of peripheral blood stem cells, we reinfuse the ATG (pig) 20mg/kg/d×2d, after transplantation we reinfused the ATG (pig) 20mg/kg/d×2d for in vivo purging.1 case occurred in the pretreatment of fungal sepsis, use only CTX 50mg/kg/d×4d, ATG is not used in vivo purging, and 1 case with autoimmune hemolytic anemia was not using ATG, but after transplantation +8d and+1 d we use the rituximab 600mg/d (375mg/m2) for in vivo purging. The median transfusion mononuclear cells (MNC) is greater than 5.0×108/kg, the median CD34 + cells greater than 2.0×106/kg, oral prednisone after transplantation 5～10 mg/d or mycophenolate mofetil (MMF) 0.5g/d for maintenance therapy. Results 17 patients of hematopoietic function recovered smoothly after transplantation, absolute neutrophil count (ANC) at a median time of +9 d (+8 d～+11 d) engraftment, the median time to platelets in the +12 d (+9 d～+15 d). Stem cell mobilization in the process of disease activity occurred in 5 patients, after prednisone was added they were controlled, 1 case with autoimmune hemolytic anemia after transplantation, reticulocytes returned to normal, bilirubin returned to normal, no recurrence of hemolytic performance. After transplantation in 5 months, Coomb's test was negative, all with connective tissue diseases caught in about 1 month after transplantation, skin rashes and joint pain gradually disappeared, SIEDAI decreased to 5 points or less, urine protein decreased or disappeared. Review 3 months after transplantation, autoantibodies titer decreased. Median follow-up of all patients to 42.6 months after transplantation,5 patients died, both in patients with systemic lupus erythematosus,3 cases of recurrence, were patients with systemic lupus erythematosus. Hematopoietic function in other patients with good recovery, the condition is sustained remission. Conclusions APBSCT is a effective treatment for autoimmune diseases,but we have strictly indications for AID. We should note the possibility of infection and disease activity during the transplantation process. After transplantation we should pay attention to the occurrence of fatal interstitial pneumonia.
Objective To explore the allogeneic hematopoietic stem cell transplantation for patients with X linked adrenoleukodystrophy (X-ALD). Methods 2 cases with X-ALD have eurological symptoms received allogeneic stem cell transplantation. We used Fludarabine (150mg/m2)+intravenous busulfan (9.6mg/kg)+pig anti-human thymocyte globulin (100mg/kg) for non-myeloablative pretreatment,1 patient received transfusion of double unrelated umbilical cord blood, and the other 1 patient received transfusion of father's HLA 5/6 by the consistency of granulocyte colony stimulating factor (G-CSF) mobilized peripheral blood stem cells. Unrelated cord blood transplantation to prevent graft versus host disease (GVHD) with cyclosporine A (CsA) combined mycophenolate mofetil (MMF) program, HLA 5/6 matched transplant to prevent GVHD with CsA combined short course MTX, was added on the basis of mycophenolate mofetil (MMF) program. Results Two patients of hematopoietic function recovered smoothly after transplantation, but the unrelated cord blood transplantation in patients with short tandem repeat (STR-PCR) analysis showed that the cord blood is not implanted, father's HLA 5/6 matched donor transplant get a complete chimera, cord blood transplant patients after resume their own autologous peripheral blood stem cell transfusion, white blood cells and platelet recovery. Cord blood transplantation in patients with no graft-versus-host disease (GVHD), performance of the migration process in the nervous system diseases have increased. The other patient received the father's HLA 5/6 matched transplant patients with gradeⅡacute GVHD,Ⅲgrade viral hemorrhagic cystitis, cytomegalovirus viremia were improved after treatment, but stay in bed longer, decreased activity. Early testing long chain fatty acids decreased compared with before transplantation. Conclusions Experience with review of the literature shows that allogeneic hematopoietic stem cell transplantation is a feasible and effective treatment method for X-ALD, but not obvious early symptoms in the nervous system in patients with good effect, patients in the transplant process may damage the nervous system, and the efficacy of transplantation still need long-term observation.
目的探讨异基因造血干细胞移植(allo-HSCT)治疗重型再生障碍性贫血(SAA)的方法和疗效。方法对30例SAA的患者进行了allo-HSCT。男18例,女12例,中位年龄25岁(3岁～48岁)。其中非血缘脐带血移植2例,非血缘成人供者移植4例,人类白细胞抗原(HLA)相合的亲缘移植19例,HLA一个位点不合的亲缘移植5例,其中3例患者采用环磷酰胺(200mg/kg)+猪抗人胸腺淋巴细胞球蛋白(100mg/kg)的非清髓性预处理,余患者均采用环磷酰胺(100-120mg/kg)+氟达拉宾(150mg/m2)+猪抗人胸腺淋巴细胞球蛋白(100mg/kg)。其中15例采用的是粒细胞集落刺激因子动员的骨髓联合外周血干细胞移植,10例采用粒细胞集落刺激因子动员的外周血干细胞移植,3例采用的是粒细胞集落刺激因子动员的骨髓,2例采用的是双份非血缘脐带血输注。预防移植物抗宿主病(GVHD)在HLA全合的亲缘移植采用环胞菌素A(CsA)联合短疗程甲氨蝶呤(MTX)的方案,对于HLA不合的亲缘移植和非血缘成人供者移植移植在CsA联合短疗程MTX的方案基础上加用霉酚酸酯(MMF)的方案,对于非血缘脐带血移植采用CsA联合霉酚酸酯(MMF)的方案。结果除3例患者在移植期间死亡外(1例脐带血移植患者在移植后18天死于感染,1例在移植后9天死于死于感染性休克,1例在移植后8天死于重度肝静脉闭塞病引起的多器官功能衰竭),1例患者血小板未植活,后再次输注供者外周血干细胞后获得植活外,余患者移植后造血恢复顺利,于中位+12天(+6～+21天)WBC植入,+15天(+9～+30天)PLT植入,除1例脐带血移植患者移植物未植入,自身恢复外,余患者+30天行患者骨髓STR-PCR检测显示为完全供者的基因型,中位随访了25.6月(0.3月～84月),所有患者的总生存率(OS)是83.3%。在可评价的患者中,急性移植物抗宿主病(aGVHD)的发生率为11.1%(3/27),其中Ⅲ的aGVHD仅为1例,慢性移植物抗宿主病(cGVHD)的发生率为21.7%(5/23),其中广泛型为8.7%(2/23)。结论异基因造血干细胞移植是治疗重型再生障碍性贫血的有效方法,但非脐带血干细胞植入不理想,需谨慎,亲缘HLA全合的移植与HLA一个位点不合的移植在干细胞植入和总生存率方面无差异,亲缘移植患者在使用骨髓联合外周血干细胞移植还是单用外周血干细胞移植两者在干细胞植入方面亦无差异。非血缘成人供者移植的晚期排斥率增加,尚需优化预处理方案以防止晚期植入失败。
目的探讨自体外周血干细胞移植(APBSCT)联合免疫抑制剂治疗自身免疫性疾病(AID)的初步疗效。方法对17例AID患者进行APBSCT同时联合或不联合使用猪抗胸腺淋巴细胞球蛋白(ATG)或利妥昔单抗体内净化。其中16例患者为系统性红斑狼疮,1例为重叠综合征(系统性红斑狼疮合并系统性硬化症),1例为自身免疫性溶血性贫血。17例均采用环磷酰胺(CTX) 4g/m2化疗联合粒细胞集落刺激因子(G-CSF) 5μg/kg/d动员患者的外周血干细胞,14例患者予CTX 50mg/kg/d×4d预处理后回输保存的外周血干细胞,1例患者予BEAM方案预处理后回输保存的外周血干细胞,回输前予ATG(猪)20mg/kg/d×2d,回输后予ATG(猪)20mg/kg/d×2d行体内净化。1例在预处理中出现真菌性败血症而仅使用CTX 50mg/kg/d×4d预处理,未使用ATG行体内净化,1例自身免疫性溶血性贫血患者未使用ATG,而是分别于移植后+1d及+8d予抗利妥昔单抗600mg/d (375mg/m2)行体内净化。回输中位单个核细胞(MNC)大于5.0×108/kg,中位CD34+细胞大于2.0×106/kg,移植后口服泼尼松5～10 mg/d或霉酚酸酯(MMF) 0.5g/d维持治疗。结果17例患者移植后造血均恢复顺利,中性粒细胞绝对计数(ANC)于中位时间+9d(+8d～+11d)植活,血小板于于中位时间+12d(+9d～+15d)。干细胞动员过程中有5例患者出现疾病活动,加用泼尼松后控制。1例自身免疫性溶血性贫血患者在移植后网织红细胞降至正常,胆红素恢复正常,未再发生溶血表现。移植后5月Coomb's试验转阴,所有结缔组织病患者均于移植后1个月左右皮疹及关节疼痛逐渐消失,SIEDAI降至5分以下,尿蛋白减少或消失。移植后3月复查自身抗体滴度下降。所有患者中位随访至移植后42.6个月,5例患者死亡,均为系统性红斑狼疮的患者,3例复发,亦为系统性红斑狼疮,余患者造血功能恢复良好,病情处于持续缓解状态。结论APBSCT是治疗自身免疫性疾病的有效方法之一,要严格掌握适应症,要注意在移植过程中有感染和疾病活动的可能,移植后要注意致命性间质性肺炎的发生。
目的探讨异基因造血干细胞移植治疗X连锁的肾上腺脑白质营养不良(X-ALD)的方法和可行性。方法对2例已经有神经系统症状的X-ALD的患者进行了异基因造血干细胞移植。均采用氟达拉宾(150mg/m2)+白消安注射液(9.6mg/kg)+猪抗人胸腺淋巴细胞球蛋白(100mg/kg)的非清髓性预处理后,1例患者回输了非血缘双份脐带血,另1例患者回输父亲HLA 5/6相合的经粒细胞集落刺激因子(G-CSF)动员的外周血干细胞。非血缘脐带血移植预防移植物抗宿主病(GVHD)采用环胞菌素A(CsA)联合霉酚酸酯(MMF)的方案,亲缘父亲HLA 5/6相合的移植GVHD采用CsA联合短疗程甲氨蝶呤(MTX)的基础上加用霉酚酸酯(MMF)的方案。结果两例患者移植后造血恢复顺利,但行非血缘脐带血移植患者短串联重复序列(STR-PCR)检测显示为脐带血未植入,亲缘父亲HLA 5/6相合的移植获得供者的完全嵌合体,行脐带血移植患者白细胞自行恢复,血小板在回输备用的自体外周血干细胞后恢复。脐带血移植患者无移植物抗宿主病(GVHD)表现,在移植过程中神经系统病变有加重。另一例接受父亲HLA 5/6相合移植的患者发生Ⅱ度的急性GVHD,Ⅲ级的病毒性出血性膀胱炎,巨细胞病毒血症,均经治疗后好转,但卧床时间较长,活动能力下降,早期测长链脂肪酸较移植前有所下降。结论本中心经验结合文献复习认为异基因造血干细胞移植是一种可行的治疗X-ALD的有效方法,但对早期神经系统症状不明显的患者疗效较好,在移植过程中患者的神经系统损伤可能会加重,且移植的疗效尚需长期观察。
Objective To improve the conditioning regimen of anti-tumor effect, we explore the of efficacy and toxicity with once-daily intravenous busulfan (IV Bu)-based conditioning regimen for allogeneic hematopoietic stem cell transplantation (allo-HSCT). Methods Of 27 patients (25 cases with hematologic malignancies and 2 cases with adrenoleukodystrophy) were used once-dailyⅣBu with the improvement of busulfan/ cyclophosphamide (Bu/Cy), improvement of Bu/Cy + Pig anti-human thymocyte globulin (ATG) and fludarabine (Flu)/busulfan+ pig ATG conditioning regimens for allo-HSCT.The median age of patients was 31 years (3 years to 61 years). In which genetic human leukocyte antigen (HLA) full matched transplantation in 19 cases, relatives of HLA mismatched-transplantation in 4 cases, unrelated adult donor transplantation in 3 cases, unrelated cord blood transplantation in 1 case. Used in the pretreatment dose of IV Bu daily 3.2mg.kg-1.d-1, the daily dose was diluted to 10 times the original solution volume, the use of infusion pump completed the first injection, infusion time for 4 hours. Collected blood samples from using the IV Bu process started after the 2h,3.9h,6h,8h,12h,16h,22h in seven time points, the use of liquid chromatography to detect the intravenous busulfan at various time points blood concentration, and record related toxicity, the case of complications after transplantation,and survival and the primary disease condition.
Results Median follow-up of 8 months (0.3 months to 18 months). The median concentration of busulfan clearance 0.067ml/min/kg, the average daily area under the curve is 13877.5ug/L*h. After transplantation 1 patient died of cerebral hemorrhage in 10 days, stem cells are not implanted, the more than 30 days after transplantation in patients with short tandem repeat lines (STR-PCR) test, only 1 case with adrenoleukodystrophy patients received cord blood transplantation is not implanted, the remaining patients showed complete donor for the genotypes.3 patients had mild mucositis,11 patients had mild gastrointestinal reactions,7 patients had abnormal liver function (including 6 cases of mild reversible abnormalities in 1 case severe jaundice),6 cases of hemorrhagic cystitis, but were delayed and no one case occured epilepsy and hepatic veno-occlusive disease (VOD). In the evaluable patients, incidence of acute graft-versus-host disease (aGVHD) was 64.0% (16/25), in which the degree of aGVHDⅢ～Ⅳonly in 28.0%(7/25), the incidence of chronic graft-versus-host Disease (cGVHD) 77.0%(17/22), the extensive type was 41.0% (9/22). Conclusions Once-daily IV Bu allo-HSCT conditioning regimen has good plasma stability, easy to use, safe and effective, and good clinical tolerance, toxicity did not increase to overcome the oral busulfan bioavailability is low and difficult to ensure accurate dosage.
Objective To explore the method and effect of allogeneic hematopoietic stem cell transplantation (allo-HSCT) for patients with severe aplastic anemia (SAA). Methods 30 cases with SAA patients received allo-HSCT.18 males and 12 females, median age 25 years (3 years to 48 years). Including 2 cases reveived unrelated cord blood transplantation, unrelated adult donor transplantation in 4 cases, human leukocyte antigen (HLA) matched transplantation in 19 cases, HLA one locus incompatible transplants in 5 cases,3 patients were treated with cyclophosphamide (200mg/kg)+ pig anti-human thymocyte globulin (100mg/kg) of non-myeloablative conditioning, the other patients were treated with cyclophosphamide (100～120mg/kg)+Fludarabine (150mg/m2)+pig anti-human thymocyte globulin (100mg/kg). Among them,15 cases were reveived the granulocyte colony stimulating factor to mobilize bone marrow combined peripheral blood stem cell transplantation,10 patients reveived granulocyte colony stimulating factor mobilized peripheral blood stem cell transplantation,3 cases reveived bone marrow of granulocyte colony stimulating factor mobilization,2 cases received double unrelated umbilical cord blood infusion. Prevention of graft versus host disease (GVHD) in the matched relatives of HLA transplantation with cyclosporine A (CsA) combined short course methotrexate (MTX) program, the affinity for the HLA one locus mismatched transplants and unrelated donor transplantation received CsA combined transplantation program short course MTX based on the use of mycophenolate mofetil (MMF) program, for unrelated cord blood transplantation mycophenolate mofetil combined with CsA (MMF) program. Results In addition 3 patients died during the transplant outside (n=1 cord blood transplant patients died of infection 18 days after transplantation,1 patient died 9 days after transplantation died of septic shock,1 patient died 8 days after transplantation and severe hepatic veno-occlusive disease caused and multiple organ failure),1 patient without platelet engraftment, again obtained engraftment after the infusion of donor peripheral blood stem cells, the hematopoietic recovery after transplantation in patients over the smooth, the median day+12 (+6 To+21 days) WBC implantation,+15 days (+9 to+30 days) PLT implantation in patients with cord blood transplantation in 1 patient without graft implantation, self-recovery, the other patients were+30 days STR-PCR analysis showed that bone marrow is completely donor genotype, with a median follow-up of 25.6 months (0.3 months to 84 months), overall survival for all patients (OS) was 83.3%. In the evaluable patients, the incidence of acute graft-versus-host disease (aGVHD) was 11.1%(3 /27), in which only 1 occurredⅢgrade aGVHD, incidence of chronic graft versus host disease (cGVHD) was 21.7%(5/23), which extensive type was 8.7%(2/23).
Conclusions Allogeneic hematopoietic stem cell transplantation is the effective treatment for severe aplastic anemia, but cord blood stem cells will need to be cautious, HLA matched patients and one locus mismatched patients of implantation of stem cell transplantation and overall survival was no difference, in the use of bone marrow transplant patients peripheral blood stem cell transplantation in the joint or single peripheral blood stem cell transplantation with stem cells both in terms of implantation has no difference. Unrelated donor transplantation in adults with advanced rejection rate increases, still need to optimize the conditioning regimen to prevent late implant failure.
Objective To explore the efficacy of autologous peripheral blood stem cell transplantation (APBSCT) combined immunosuppressive for autoimmune diseases (AID).
Methods AID patients in 17 cases received APBSCT also use the pig with or without antithymocyte globulin (ATG) or rituximab in vivo purging. Of these,16 patients were systemic lupus erythematosus,1 case with overlap syndrome (systemic sclerosis systemic and lupus erythematosus),1 case of autoimmune hemolytic anemia.17 patients were using cyclophosphamide (CTX) 4g/m2 chemotherapy and granulocyte colony stimulating factor (G-CSF) 5μg/kg/d mobilized peripheral blood stem cells in patients,14 patients received tCTX 50mg/kg/d×4d before reinfusion of peripheral blood stem cell preservation, and 1 patient received the BEAM conditioning. Before pretreatment transfusion of peripheral blood stem cells, we reinfuse the ATG (pig) 20mg/kg/d×2d, after transplantation we reinfused the ATG (pig) 20mg/kg/d×2d for in vivo purging.1 case occurred in the pretreatment of fungal sepsis, use only CTX 50mg/kg/d×4d, ATG is not used in vivo purging, and 1 case with autoimmune hemolytic anemia was not using ATG, but after transplantation +8d and+1 d we use the rituximab 600mg/d (375mg/m2) for in vivo purging. The median transfusion mononuclear cells (MNC) is greater than 5.0×108/kg, the median CD34 + cells greater than 2.0×106/kg, oral prednisone after transplantation 5～10 mg/d or mycophenolate mofetil (MMF) 0.5g/d for maintenance therapy. Results 17 patients of hematopoietic function recovered smoothly after transplantation, absolute neutrophil count (ANC) at a median time of +9 d (+8 d～+11 d) engraftment, the median time to platelets in the +12 d (+9 d～+15 d). Stem cell mobilization in the process of disease activity occurred in 5 patients, after prednisone was added they were controlled, 1 case with autoimmune hemolytic anemia after transplantation, reticulocytes returned to normal, bilirubin returned to normal, no recurrence of hemolytic performance. After transplantation in 5 months, Coomb's test was negative, all with connective tissue diseases caught in about 1 month after transplantation, skin rashes and joint pain gradually disappeared, SIEDAI decreased to 5 points or less, urine protein decreased or disappeared. Review 3 months after transplantation, autoantibodies titer decreased. Median follow-up of all patients to 42.6 months after transplantation,5 patients died, both in patients with systemic lupus erythematosus,3 cases of recurrence, were patients with systemic lupus erythematosus. Hematopoietic function in other patients with good recovery, the condition is sustained remission. Conclusions APBSCT is a effective treatment for autoimmune diseases,but we have strictly indications for AID. We should note the possibility of infection and disease activity during the transplantation process. After transplantation we should pay attention to the occurrence of fatal interstitial pneumonia.
Objective To explore the allogeneic hematopoietic stem cell transplantation for patients with X linked adrenoleukodystrophy (X-ALD). Methods 2 cases with X-ALD have eurological symptoms received allogeneic stem cell transplantation. We used Fludarabine (150mg/m2)+intravenous busulfan (9.6mg/kg)+pig anti-human thymocyte globulin (100mg/kg) for non-myeloablative pretreatment,1 patient received transfusion of double unrelated umbilical cord blood, and the other 1 patient received transfusion of father's HLA 5/6 by the consistency of granulocyte colony stimulating factor (G-CSF) mobilized peripheral blood stem cells. Unrelated cord blood transplantation to prevent graft versus host disease (GVHD) with cyclosporine A (CsA) combined mycophenolate mofetil (MMF) program, HLA 5/6 matched transplant to prevent GVHD with CsA combined short course MTX, was added on the basis of mycophenolate mofetil (MMF) program. Results Two patients of hematopoietic function recovered smoothly after transplantation, but the unrelated cord blood transplantation in patients with short tandem repeat (STR-PCR) analysis showed that the cord blood is not implanted, father's HLA 5/6 matched donor transplant get a complete chimera, cord blood transplant patients after resume their own autologous peripheral blood stem cell transfusion, white blood cells and platelet recovery. Cord blood transplantation in patients with no graft-versus-host disease (GVHD), performance of the migration process in the nervous system diseases have increased. The other patient received the father's HLA 5/6 matched transplant patients with gradeⅡacute GVHD,Ⅲgrade viral hemorrhagic cystitis, cytomegalovirus viremia were improved after treatment, but stay in bed longer, decreased activity. Early testing long chain fatty acids decreased compared with before transplantation. Conclusions Experience with review of the literature shows that allogeneic hematopoietic stem cell transplantation is a feasible and effective treatment method for X-ALD, but not obvious early symptoms in the nervous system in patients with good effect, patients in the transplant process may damage the nervous system, and the efficacy of transplantation still need long-term observation.
引文
[1]Santos GW, Tutschka PJ, Brookmeyer R, et al. Marrow transplantation for acute nonlymphocytic leukemia after treatment with busulfan and cyclophosphamide. N Engl J Med.1983,309(22):1347-1353.
[2]Lu C, Braine HG, Kaizer H, et al. Preliminary results of high-dose busulfan and cyclophosphamide with syngeneic or autologous bone-marrow rescue. Cancer Treat Rep. 1984,68(5):711-717.
[3]Tutschka PJ, Copelan EA, Klein JP. Bone marrow transplantation for leukemia following a new busulfan and cyclophosphamide regimen. Blood.1987,70(5):1382-1388.
[4]McDonald GB, Sharma P, Matthews DE,et al. The clinical course of 53 patients with venocclusive disease of the liver after marrow transplantation. Transplantation. 1985,39(6):603-608.
[5]Benet LZ,Sheiner LB.Pharmacokinetics:the dynamics of drug absorption, distribution, andelimi-nation. In:Goodman Gilman A,Goodman LS, Rall TW, Murad F,eds.Goodman and Gilman,s the Pharmacological Basis of Therapeutics.7thed. NewYork,NY:MacMillan; 1985:8.
[6]Bhagwatwar HP, Phadungpojna S, Chow DS, et al. Formulation and stability of busulfan for intravenous administration in high-dose chemotherapy. Cancer Chemother Pharmacol.1996,37(5):401-408.
[7]Andersson BS, Kashyap A, Gian V, et al. Conditioning therapy with intravenous busulfan and cyclophosphamide (IV BuCy2) for hematologic malignancies prior to allogeneic stem cell transplantation: a phase Ⅱ study. Biol Blood Marrow Transplant. 2002,8(3):145-154.
[8]Kashyap A, Wingard J, Cagnoni P, et al. Intravenous versus oral busulfan as part of a busulfan/cyclophosphamide preparative regimen for allogeneic hematopoietic stem cell transplantation: decreased incidence of hepatic venoocclusive disease (HVOD), HVOD-related mortality, and overall 100-day mortality. Biol Blood Marrow Transplant. 2002,8(9):493-500.
[9]Grochow LB, Noe DA, Ettinger DS, et al. A phase I trial of trimetrexate glucuronate (NSC 352122) given every 3 weeks:clinical pharmacology and pharmacodynamics. Cancer Chemother Pharmacol.1989,24(5):314-320.
[10]Grochow LB. Busulfan disposition: the role of therapeutic monitoring in bone marrow transplantation induction regimens. Semin Oncol.1993,20(4 Suppl 4):18-25.
[11]Hassan M, Oberg G, Ehrsson H, et al. Pharmacokinetic and metabolic studies of high-dose busulphan in adults. Eur J Clin Pharmacol.1989,36(5):525-530.
[12]Vassal G, Deroussent A, Hartmann O, et al. Dose-dependent neurotoxicity of high-dose busulfan in children: a clinical and pharmacological study. Cancer Res. 1990,50(19):6203-6207.
[13]Slattery JT, Sanders JE, Buckner CD, et al. Graft-rejection and toxicity following bone marrow transplantation in relation to busulfan pharmacokinetics. Bone Marrow Transplant. 1995,16(1):31-342.
[14]Andersson BS, Thall PF, Madden T, et al. Busulfan systemic exposure relative to regimen-related toxicity and acute graft-versus-host disease:defining a therapeutic window for i.v. BuCy2 in chronic myelogenous leukemia. Biol Blood Marrow Transplant. 2002,8(9):477-485.
[15]Russell JA, Tran HT, Quinlan D, et al. Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes. Biol Blood Marrow Transplant. 2002,8(9):468-476.
[16]Ryu SG, Lee JH, Choi SG, et al. Randomized comparison of four-times-daily versus once-daily intravenous busulfan in conditioning therapy for hematopoietic cell transplantation. Biol Blood Marrow Transplant,2007,13(9):1095-1105.
[17]Zhang P, Chen BJ, Chao NJ. Prevention of GVHD without losing GVL effect: windows of opportunity. Immunol Res.2011,49(1-3):49-55.
[18]肖毅,张东华,黄伟,等.造血干细胞移植治疗血液病及实体瘤的疗效分析.华中科技大学学报(医学版),2006,35(5)：644-652.
[19]Fisher VL, Barnes YJ, Nuss SL. Pretransplant conditioning in adults and children: dose assurance with intravenous busulfan. Oncol Nurs Forum.2006,33(2):E36-43.
[20]Kaplan EL,Meier P.Nonparametric estimation From incomplete observations.J Am Stat Assoc.1958,53:457-481.
[21]Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep.1966,50(3):163-170.
[22]Cox DR. Regression models and life tables (with discussion).J R Stat Soc B.1972,34:187-220.
[23]Therneau TM, Grambsch P. Modeling Survival Data.New York,NY: Springer;2000.
[24]Cleveland, WS:Robust locally-weighted regression and smoothing scatterplots.J Am Stat Assoc.1979,74:829-836.
[25]Therneau TM, Grambsch P. Modeling Survival Data:Extending the Cox Model. Chap.3.7.New York,NY:Springer;2000,68-77.
[26]Congdon P.Bayesian Statistical Modeling.New York,NY:Wiley;2001.
[27]Venables WN,Ripley BD.Modern Applied Statistics With Splus.3rded. NewYork, NY: Springer; 1999.
[28]Therneau TM: A package for survival analysis in S. Rochester, MN:Mayo Clinic Foundation,1997.
[29]Andersson BS, Madden T, Tran HT, et al. Acute safety and pharmacokinetics of intravenous busulfan when used with oral busulfan and cyclophosphamide as pretransplantation conditioning therapy: a phase I study. Biol Blood Marrow Transplant. 2000,6(5A):548-554.
[30]Gibaldi M, Perrier D.Pharmacokinetics. 2nd ed.New York, NY:Marcel Dekker;1982:409-417.
[31]D'Argenio DZ,Schumitzky A.ADAPT II User's Guide:Pharmacokinetic/ Pharmacodynamic Systems Analysis Software. LosAngeles,CA:Biomedical Simulations Resource; 1997.
[32]Hassan M, Nilsson C, Hassan Z, et al.A phase II trial of liposomal busulphan as an intravenous myeloablative agent prior to stem cell transplantation: 500 mg/m(2) as a optimal total dose for conditioning.Bone Marrow Transplant.2002,30(12):833-841.
[33]Deeg HJ, Storer B, Slattery JT, et al. Conditioning with targeted busulfan and cyclophosphamide for hemopoietic stem cell transplantation from related and unrelated donors in patients with myelodysplastic syndrome. Blood.2002,100(4):1201-1207.
[34]Thall PF, Champlin RE, Andersson BS. Comparison of 100-day mortality rates associated with i.v. busulfan and cyclophosphamide vs other preparative regimens in allogeneic bone marrow transplantation for chronic myelogenous leukemia:Bayesian sensitivity analyses of confounded treatment and center effects. Bone Marrow Transplant. 2004,(12):1191-1199.
[35]Kashyap A, Wingard J, Cagnoni P, et al.Intravenous versus oral busulfan as part of a busulfan/cyclophosphamide preparative regimen for allogeneic hematopoietic stem cell transplantation: decreased incidence of hepatic venoocclusive disease (HVOD), HVOD-related mortality, and overall 100-day mortality.Biol Blood Marrow Transplant. 2002,8(9):493-500.
[36]肖毅,张义成,张东华,等.采用静脉注射白消安预处理方案的异基因造血干细胞移植治疗恶性血液病一例.中华器官移植杂志.2006,27(11)：695-697.
[37]Small TN, Young JW, Castro-Malaspina H, et al. Intravenous busulfan and melphalan, tacrolimus, and short-course methotrexate followed by unmodified HLA-matched related or unrelated hematopoietic stem cell transplantation for the treatment of advanced hematologic malignancies. Biol Blood Marrow Transplant.2007,13(2):235-244.
[38]Andersson BS, Kashyap A, Gian V, et al.Conditioning therapy with intravenous busulfan and cyclophosphamide (IV BuCy2) for hematologic malignancies prior to allogeneic stem cell transplantation: a phase Ⅱ study. Biol Blood Marrow Transplant.2002, 8(3):145-154.
[39]Grochow LB. Parenteral busulfan:is therapeutic monitoring still warranted? Biol Blood Marrow Transplant.2002,8(9):465-467.
[40]Cho YH, Lim HA, Lee MH, et al. Pharmacokinetics and.tolerability of intravenous busulfan in hematopoietic stem cell transplantation. Clin Transplant.2007,21 (3):417-422.
[41]Ringden O, Labopin M, Tura S, et al.A comparison of busulphan versus total body irradiation combined with cyclophosphamide as conditioning for autograft or allograft bone marrow transplantation in patients with acute leukaemia. Acute Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT).Br J Haematol. 1996,93(3):637-645.
[42]Kim SE, Lee JH, Choi SJ, et al. Morbidity and non-relapse mortality after allogeneic bone marrow transplantation in adult leukemia patients conditioned with busulfan plus cyclophosphamide:a retrospective comparison of oral versus intravenous busulfan. Haematologica.2005,90(2):285-286.
[43]童秀珍,许多荣,邹外一,等.静脉剂型白消安为主的预处理方案对接受异基因造血干细胞移植的白血病患者的疗效及相关毒性.癌症.2007,26(8)：914-918.
[44]Andersson BS, Madden T, Tran HT, et al.Acute safety and pharmacokinetics of intravenous busulfan when used with oral busulfan and cyclophosphamide as pretransplantation conditioning therapy: a phase I study. Biol Blood Marrow Transplant. 2000,6(5):548-554.
[45]Lee JH, Choi SJ, Lee JH, et al. Decreased incidence of hepatic veno-occlusive disease and fewer hemostatic derangements associated with intravenous busulfan vs oral busulfan in adults conditioned with busulfan + cyclophosphamide for allogeneic bone marrow transplantation. Ann Hematol.2005,84(5):321-330.
[46]Shimoni A, Bielorai B, Toren A, et al. Intravenous busulfan-based conditioning prior to allogeneic hematopoietic stem cell transplantation: myeloablation with reduced toxicity. Exp Hematol.2003,31(5):428-434.
[47]Aggarwal C, Gupta S, Vaughan WP, et al. Improved outcomes in intermediate- and high-risk aggressive non-Hodgkin lymphoma after autologous hematopoietic stem cell transplantation substituting intravenous for oral busulfan in a busulfan, cyclophosphamide, and etoposide preparative regimen. Biol Blood Marrow Transplant.2006,12(7):770-777.
[48]Hoy SM, Lyseng-Williamson KA. Intravenous busulfan:in the conditioning treatment of pediatric patients prior to hematopoietic stem cell transplantation. Paediatr Drugs.2007, 9(4):271-278.
[49]Lee MY, Chiou TJ, Bai LY, et al.Intravenous busulfan as preparative regimen in pediatric patients receiving hematopoietic stem cell transplantation: the preliminary experience in Taiwan. J Chin Med Assoc.2004,67(3):117-122.
[50]Kletzel M, Jacobsohn D, Duerst R. Pharmacokinetics of a test dose of intravenous busulfan guide dose modifications to achieve an optimal area under the curve of a single daily dose of intravenous busulfan in children undergoing a reduced-intensity conditioning regimen with hematopoietic stem cell transplantation. Biol Blood Marrow Transplant, 2006,12(4):472-479.
[51]Dalle JH, Wall D, Theoret Y, et al. Intravenous busulfan for allogeneic hematopoietic stem cell transplantation in infants:clinical and pharmacokinetic results. Bone Marrow Transplant.2003,32(7):647-651.
[52]Vaughan WP,Cagnoni P,Fernandez H,etal.De-Creased incidence of and risk factors for hepatic veno-occlusive disease with an intravenous busulfan(BU) containing preparative regimen for hematopoietic stem cell transplantation(HSCT) [abstract].Blood.1998,92:516a.
[53]McDonald GB, Slattery JT, Bouvier ME, et al. Cyclophosphamide metabolism, liver toxicity, and mortality following hematopoietic stem cell transplantation. Blood. 2003,101(5):2043-2048.
[54]Gandhi V, Plunkett W. Cellular and clinical pharmacology of fludarabine. Clin Pharmacokinet.2002,41(2):93-103.
[55]de Lima M, Couriel D, Thall PF, et al. Once-daily intravenous busulfan and fludarabine:clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS. Blood. 2004,104(3):857-864.
[56]Bornhauser M, Storer B, Slattery JT, et al.Conditioning with fudarabine and targeted busulfan for tansplantation of allogeneic hematopoietic stem cells. Blood. 2003,102:820-826.
[57]Dix SP, Wingard JR, Mullins RE, et al. Association of busulfan area under the curve with veno-occlusive disease following BMT. Bone Marrow Transplant. 1996,17(2):225-230.
[58]Madden T, Nguyen J, Thapar N, et al. Thepharmacokinetics (PK) of once daily intravenous busulfan(Bu) aspart of pretransplant preparative regimens; a comparison to Q 6 hourly dosing [abstract].Blood.2003,102:477a.
[59]Blume KG, Kopecky KJ, Henslee-Downey JP, et al. A prospective randomized comparison of total body irradiation-etoposide versus busulfan-cyclophosphamide as preparatory regimens for bone marrow transplantation in patients with leukemia who were not in first remission: a Southwest Oncology Group study. Blood.1993,81(8):2187-2193.
[60]Gupta V, Lazarus HM, Keating A. Myeloablative conditioning regimens for AML allografts:30 years later. Bone Marrow Transplant.2003,32(10):969-978.
[61]Thomas ED, Buckner CD, Banaji M, et al. One hundred patients with acute leukemia treated by chemotherapy, total body irradiation, and allogeneic marrow transplantation. Blood.1977,49(4):511-533.
[62]Estey E, deLima M, Strom S, et al. Long-term follow-up of patients with newly diagnosed acute myeloid leukemia treated at the University of Texas M.D. Anderson Cancer Center. Cancer.1997,80(11 Suppl);2176-2180.
[1]Marsh JC, Ball SE, Darbyshire P,et al. Guidelines for the diagnosis and management of acquired aplastic anaemia. Br J Haematol.2003,123(5):782-801.
[2]George ER, Storb R. Allogeneic Hematopoietic Cell Transplantation for Aplastic Anemia. In:Blume KG, Forman SJ, Thomas ED, editors. Thomas'O Hematopoietic Cell Transplantation. Boston:Blackwell;2004. p.981-1001.
[3]Bacigalupo A,. Hows J, Gluckman E,et al. Bone marrow transplantation (BMT) versus immunosuppression for the treatment of severe aplastic anaemia (SAA):a report of the EBMT SAA working party. Br J Haematol.1988,70(2):177-182.
[4]Doney K, Leisenring W, Storb R,et al. Primary treatment of acquired aplastic anemia: outcomes with bone marrow transplantation and immunosuppressive therapy. Seattle Bone Marrow Transplant Team. Ann Intern Med.1997,126(2):107-115.
[5]Passweg JR, Socie G, Hinterberger W,et al. Bone marrow transplantation for severe aplastic anemia: has outcome improved? Blood.1997,90(2):858-864.
[6]Bacigalupo A, Brand R, Oneto R,et al. Treatment of acquired severe aplastic anemia: bone marrow transplantation compared with immunosuppressive therapy--The European Group for Blood and Marrow Transplantation experience. Semin Hematol. 2000,37(1):69-80.
[7]Ades L, Mary JY, Robin M,et al. Long-term outcome after bone marrow transplantation for severe aplastic anemia. Blood.2004,103(7):2490-2497.
[8]Storb R, Etzioni R, Anasetti C et al. Cyclophosphamide combined with antithymocyte globulin in preparation for allogeneic marrow transplants in patients with aplastic anemia.Blood,1994,84:941-949.
[9]Georges GE, Storb R. Allogeneic hematopoietic cell transplantation for aplastic anemia. In: Blume KG, Forman SJ, AppelbaumFR (eds) Thomas' Hematopoietic Cell Transplantation.Blackwell Publishing Ltd: Oxford,2004:981-1001.
[10]Deeg HJ, Anasetti C, Petersdorf E et al. Cyclophosphamide plus ATG conditioning is insuf.cient for sustained hematopoietic reconstitution in patients with severe aplastic anemia transplanted with marrow from HLA-A, B, DRB matchedunrelated donors. Blood,1994,83:3417-3418.
[11]Young NS, Calado RT, Scheinberg P. Current concepts in the pathophysiology and treatment of aplastic anemia. Blood.2006,108(8):2509-2519.
[12]Marsh JC. Treatment of acquired aplastic anemia. Haematologica.2007,92(l):2-5.
[13]Ringden O, Remberger M, Svenberg P, et al. Fludarabine-based disease-specific conditioning or conventional myeloablative conditioning in hematopoietic stem cell transplantation for treatment of non-malignant diseases. Bone Marrow Transplant. 2007,39(7):383-388.
[14]Kumar R, Prem S, Mahapatra M, et al. Fludarabine, cyclophosphamide and horse antithymocyte globulin conditioning regimen for allogeneic peripheral blood stem cell transplantation performed in non-HEPA filter rooms for multiply transfused patients with severe aplastic anemia.B one Marrow Transplant.2006,37(8):745-749.
[15]Itala M, Aho H, Remes K. Reduced-intensity conditioning and blood stem cell transplantation from an HLA-identical sibling for severe aplastic anaemia:two patients with successful engraftment but a fatal post-transplant lymphoproliferative disorder in the other. Hematol J.2004,5(5):440-443.
[16]Srinivasan R, Takahashi Y, McCoy JP,et al. Overcoming graft rejection in heavily transfused and allo-immunised patients with bone marrow failure syndromes using fludarabine-based haematopoietic cell transplantation. Br J Haematol. 2006,133(3):305-314.
[17]Resnick IB, Aker M, Shapira MY,et al. Allogeneic stem cell transplantation for severe acquired aplastic anaemia using a fludarabine-based preparative regimen. Br J Haematol. 2006,133(6):649-654.
[18]Gomez-Almaguer D, Vela-Ojeda J, Jaime-Perez JC,et al. Allografting in patients with severe, refractory aplastic anemia using peripheral blood stem cells and a fludarabine-based conditioning regimen: the Mexican experience. Am J Hematol.2006,81(3):157-161.
[19]George B, Mathews V, Viswabandya A,et al. Fludarabine and cyclophosphamide based reduced intensity conditioning (RIC) regimens reduce rejection and improve outcome in Indian patients undergoing allogeneic stem cell transplantation for severe aplastic anemia. Bone Marrow Transplant.2007,40(1):13-18.
[20]Bacigalupo A, Locatelli F, Lanino E,et al. Fludarabine, cyclophosphamide and anti-thymocyte globulin for alternative donor transplants in acquired severe aplastic anemia: a report from the EBMT-SAA Working Party. Bone Marrow Transplant. 2005,36(11):947-950.
[21]Maury S, Bacigalupo A, Anderlini P,et al. Improved outcome of patients older than 30 years receiving HLA-identical sibling hematopoietic stem cell transplantation for severe acquired aplastic anemia using fludarabine-based conditioning: a comparison with conventional conditioning regimen. Haematologica.2009,94(9):1312-1315.
[22]Zhang P, Chen BJ, Chao NJ. Prevention of GVHD without losing GVL effect: windows of opportunity. Immunol Res.2011,49(1-3):49-55.
[23]Ahn MJ, Choi JH, Lee YY, et al. Outcome of adult severe or very severe aplastic anemia treated with immunosuppressive therapy compared with bone marrow transplantation: multicenter trial. Int J Hematol,2003,78:133-138.
[24]Kanda Y, Chiba S, Hirai H, et al. Allogeneic hematopoietic stem cell transplantation from family members other than HLA-identical siblings over the last decade (1991-2000). Blood,2003,102(4):1541-1547.
[25]Davies SM, Wagner JN, Defor T, et al. Unrelated donor bone marrow transplantation for children and adolesents with aplastic anemia or myelodysplasia. Br J Haematol,1997,96(7):749-756.
[26]Margolis DA, Casper JT. Alternative-donor hematopoietic stem-cell transplantation for severe aplastic anemia. Semin Hematol.2000 Jan;37(1):43-55.
[27]Storb R, Anasetti C, Appelbaum F,et al. Marrow transplantation for severe aplastic anemia and thalassemia major. Semin Hematol.1991,28(3):235-239.
[28]Socie G, Henry-Amar M, Bacigalupo A,et al. Malignant tumors occurring after treatment of aplastic anemia. European Bone Marrow Transplantation-Severe Aplastic Anaemia Working Party. N Engl J Med.1993,329(16):1152-1157.
[29]Deeg HJ, Socie G, Schoch G,et al. Malignancies after marrow transplantation for aplastic anemia and fanconi anemia:a joint Seattle and Paris analysis of results in 700 patients. Blood.1996,87(1):386-392.
[30]Deeg HJ, O'Donnell M, Tolar J,et al. Optimization of conditioning for marrow transplantation from unrelated donors for patients with aplastic anemia after failure of immunosuppressive therapy. Blood.2006,108(5):1485-1491.
[31]Perez-Albuerne ED, Eapen M, Klein J, Gross TJ,et al. Outcome of unrelated donor stem cell transplantation for children with severe aplastic anemia. Br J Haematol. 2008,141(2):216-223.
[32]Kojima S, Matsuyama T, Kato S,et al. Outcome of 154 patients with severe aplastic anemia who received transplants from unrelated donors:the Japan Marrow Donor Program. Blood:2002,100(3):799-803.
[33]Bacigalupo A, Locatelli F, Lanino E,et al. Fludarabine, cyclophosphamide and anti-thymocyte globulin for alternative donor transplants in acquired severe aplastic anemia: a report from the EBMT-SAA Working Party. Bone Marrow Transplant. 2005,36(11):947-950.
[34]Bacigalupo A, Socie'G, Lanino E,et al. Fludarabine, cyclophosphamide, antithymocyte globulin, with or without low dose total body irradiation, for alternative donor transplants, in acquired severe aplastic anemia: a retrospective study from the EBMT-SAA working party. Haematologica.2010,95(6):976-982.
[35]Chan KW, McDonald L, Lim D,et al. Unrelated cord blood transplantation in children with idiopathic severe aplastic anemia. Bone Marrow Transplant.2008,42(9):589-595.
[36]Eapen M, Rubinstein P, Zhang MJ,et al. Outcomes of transplantation of unrelated donor umbilical cord blood and bone marrow in children with acute leukaemia:a comparison study. Lancet.2007,369(9577):1947-1954.
[37]Eapen M, Rocha V, Sanz G,et al. Effect of graft source on unrelated donor haemopoietic stem-cell transplantation in adults with acute leukaemia: a retrospective analysis. Lancet Oncol.2010,11(7):653-660.
[38]MacMillan ML, Walters MC, Gluckman E. Transplant outcomes in bone marrow failure syndromes and hemoglobinopathies. Semin Hematol.2010,47(l):37-45.
[39]Chan KW, McDonald L, Lim D,et al. Unrelated cord blood transplantation in children with idiopathic severe aplastic anemia. Bone Marrow Transplant.2008,42(9):589-595.
[40]Yoshimi A, Kojima S, Taniguchi S,et al. Unrelated cord blood transplantation for severe aplastic anemia. Biol Blood Marrow Transplant.2008,14(9):1057-1063.
[41]Deeg HJ, Amylon ID, Harris RE et al. Marrow transplants fromunrelated donors for patients with aplastic anemia: minimum effective dose of total body irradiation. Biol Blood Marrow Transplant,2001,7:208-215.
[42]Kojima S, Inaba J, Yoshimi A et al. Unrelated donor marrow transplantation in children with severe aplastic anaemia using cyclophosphamide, anti-thymocyte globulin and total body irradiation. Br J Haematol,2001,114:706-711.
[43]Vassiliou GS, Webb DK, Pamphilon D et al. Improved outcome of alternative donor bone marrow transplantation in children with severe aplastic anaemia using a conditioning regimen containing low-dose total body irradiation, cyclophosphamide and Campath. Br J Haematol,2001,114:701-705.
[44]Socie G, Henry-Amar M, Cosset JM et al. Increased incidence of solid malignant tumors after bone marrow transplantation for severe aplastic anemia. Blood,1991,78: 277-279.
[45]Bacigalupo A, Locatelli F, Lanino E, et al. Fludarabine, cyclophosphamide and anti-thymocyte globulin for alternative donor transplants in acquired severe aplastic anemia: a report from the EBMT-SAA Working Party. Bone Marrow Transplant.2005, 35:1655-1661.
[46]Urban C, Benesch M, Sykora KW, et al. Non-radiotherapy conditioning with stem cell transplantation from alternative donors in children with refractory severe aplastic anemia. Bone Marrow Transplant,2005,35:591-594.
[47]Ambulkar I, Parikh PM, Saikia T. Successful allogeneic stem cell transplantation with fludarabine-based conditioning regimen in severe aplastic anemia. J Assoc Physicians India, 2003,51:715-716.
[48]Lee JH, Choi SJ, Lee JH, et al. Non-total body irradiation containing preparative regimen in alternative donor bone marrow transplantation for severe aplastic anemia. Bone Marrow Transplant.2005,35:755-761.
[49]Bornhauser M, schuler U, Porksen G, et al. Mycophenolate mofetil and cyclosporine as graft-versus-host disease prophylax is after allogeneic blood stem cell transplantation. Transplantstion,1999,67:499-504.
[50]黄河,林茂芳,孟海涛,等.霉酚酸酣联合CsA和短程MTX预防非亲缘异基因骨做移植的急性移植物抗宿主病.中华血液学杂志,2001,22：76-78.
[51]Basara N, Kiehl MG, Blau W, et al. Mycophenolate Mofetil in the treatment of acute and chronic GVHD in hematopoitic stem cell transplant patients:four years of experience. Transplant Proc,2001,33:2121-2133.
[52]Champlin RE, Perez WS, Passweg JR,et al. Bone marrow transplantation for severe aplastic anemia: a randomized controlled study of conditioning regimens. Blood. 2007,109(10):4582-4585.
[53]Casado LF, Steegmann JL, Pico M,et al. Study of chimerism in long-term survivors after bone marrow transplantation for severe acquired aplastic anemia. Bone Marrow Transplant.1996,18(2):405-409.
[1]Abu-Shakra M, Urowitz MB, Gladman DD,et al. Mortality studies in systemic lupus erythematosus. Results from a single center. II. Predictor variables for mortality. J Rheumatol.1995,22(7):1265-1270.
[2]Cervera R, Khamashta MA, Font J,et al. Morbidity and mortality in systemic lupus erythematosus during a 5-year period. A multicenter prospective study of 1,000 patients. European Working Party on Systemic Lupus Erythematosus. Medicine (Baltimore). 1999,78(3):167-175.
[3]Austin HA 3rd, Klippel JH, Balow JE,et al. Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. N Engl J Med.1986,314(10):614-619.
[4]Bansal VK, Beto JA. Treatment of lupus nephritis:a meta-analysis of clinical trials. Am J Kidney Dis.1997,29(2):193-199.
[5]Chan TM, Li FK, Tang CS,et al. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group. N Engl J Med.2000,343(16):1156-1162.
[6} Takada K, Illei GG, Boumpas DT. Cyclophosphamide for the treatment of systemic lupus erythematosus. Lupus.2001,10(3):154-161.
[7]Alaez C, Loyola M, Murguia A, et al. Hematopoietic stem cell transplantation (HSCT): an approach to autoimmunity.Autoimmun Rev,2006,5(3):167-179.
[8]Burt RK, Verda L, Oyama Y, et al. Non-myeloablative stem cell transplantation for autoimmune diseases. Springer Semin Immunopathol.2004,26(1-2):57-69.
[9]Ikehara S, Good RA, Nakamura T,et al. Rationale for bone marrow transplantation in the treatment of autoimmune diseases. Proc Natl Acad Sci U S A.1985,82(8):2483-2487.
[10]Snowden JA, Brooks PM, Biggs JC. Haemopoietic stem cell transplantation for autoimmune diseases. Br J Haematol.1997,99(1):9-22.
[11]Burt RK, Slavin S,Burns WH,et al. Induction of tolerance in autoimmune diseases by hematopoietic stem cell transplantation:getting closer to a cure? Blood. 2002,99(3):768-784.
[12]Marmont AM. Stem cell transplantation for severe autoimmune diseases:progress and problems. Haematologica.1998,83(8):733-743.
[13]Burt RK, Traynor A, Ramsey-Goldman R. Hematopoietic stem-cell transplantation for systemic lupus erythematosus. N Engl J Med.1997,337(24):1777-1778.
[14]Burt RK, Traynor AE, Pope R,et al. Treatment of autoimmune disease by intense immunosuppressive conditioning and autologous hematopoietic stem cell transplantation. Blood.1998,92(10):3505-3514.
[15]Traynor AE, Schroeder J, Rosa RM,et al. Treatment of severe systemic lupus erythematosus with high-dose chemotherapy and haemopoietic stem-cell transplantation: a phase I study. Lancet.2000,356(9231):701-707.
[16]Traynor AE, Barr WG, Rosa RM,et al. Hematopoietic stem cell transplantation for severe and refractory lupus. Analysis after five years and fifteen patients. Lancet. 2000,356(9231):701-707.
[17]Raetz E, Beatty PG, Adams RH. Treatment of severe Evans syndrome with an allogeneic cord blood transplant. Bone Marrow Transplant,1997,20(5):427-429.
[18]Musso M, Porretto F, Crescimanno A, et al. Autologous peripheral blood stem and progenitor (CD34+) cell transplantation for systemic lupus erythematosus complicated by Evans syndrome. Lupus,1998,7(7):492-494.
[19]Paillard C, Kanold J, Halle P, et al. Two-step immunoablative treatment with autologous peripheral blood CD34(+) cell transplantation in an 8-year-old boy with autoimmune haemolytic anaemia. Br J Haematol,2000,110(4):900-902.
[20]Jindra P, Koza V, Fiser J, et al. Autologous CD34+ cells transplantation after FAMP treatment in a patient with CLL and persisting AIHA:complete remission of lymphoma with control of autoimmune complications. Bone Marrow Transplant,1999,24(2):215-217.
[21]Treon SP, Anderson KC. The use of rituximab in the treatment of malignant and nonmalignant plasma cell disorders. Semin Oncol,2000,27(6 suppl 2):79-85.
[22]Zecca M, Nobili B, Ramenghi U. Rituximab for the treatment of refractory autoimmune hemolytic anemia in children. Blood,2003,101(10):3857-3861.
[23]Hongeng S, Tardtong P, Worapongpaiboon S, et al. Successful treatment of refractory autoimmune haemolytic anaemia in a post-unrelated bone marrow transplant paediatric patient with rituximab. Bone Marrow Transplant,2002,29(10):871-872.
[24]Raj A, Bertolone S, Cheerva A, et al. Successful treatment of refractory autoimmune hemolytic anemia with monthly rituximab following nonmyeloablative stem cell transplantation for sickle cell disease. J Pediatr Hematol Oncol,2004,26(5):312-314.
[25]Endo T, Nakao S, Koizumi K, et al. Successful treatment with rituximab for autoimmune hemolytic anemia concomitant with proliferation of Epstein-Barr virus and monoclonal gammopathy in a post-nonmyeloablative stem cell transplant patient. Ann Hematol,2004,83(2):114-116.
[26]Seeliger S, Baumann M, Mohr M, et al. Autologous peripheral blood stem cell transplantation and anti-B-cell directed immunotherapy for refractory auto-immune haemolytic anaemia. Eur J Pediatr,2001,160(8):492-496.
[27]Burt RK, Traynor A, Statkute L, et al.Nonmyeloablative hematopoietic stem cell transplantation for systemic lupus erythematosus.JAMA,2006,295(5):527-535.
[28]Jayne D, Passweg J, Marmont A,et al. Autologous stem cell transplantation for systemic lupus erythematosus. Lupus.2004;13(3):168-176.
[29]Statkute L, Traynor A, Oyama Y,et al. Antiphospholipid syndrome in patients with systemic lupus erythematosus treated by autologous hematopoietic stem cell transplantation. Blood.2005,106(8):2700-2709.
[30]Dubey S, Nityanand S. Involvement of Fas and TNF pathways in the induction of apoptosis of T cells by antithymocyte globulin. Ann Hematol.2003 Aug;82(8):496-9.
[31]Young N, Speck B. Antithymocyte and antilymphocyte globulins:clinical trials and mechanism of action. Prog Clin Biol Res.1984,148:221-226.
[32]Kang I, Park SH. Infectious complications in SLE after immunosuppressive therapies. Curr Opin Rheumatol.2003,15(5):528-534.
[33]Salzberger B, Bowden RA, Hackman RC,et al. Neutropenia in allogeneic marrow transplant recipients receiving ganciclovir for prevention of cytomegalovirus disease: risk factors and outcome. Blood.1997,90(6):2502-2508.
[34]Euler HH, Harten P, Zeuner RA,et al. Recombinant human granulocyte colony stimulating factor in patients with systemic lupus erythematosus associated neutropenia and refractory infections. J Rheumatol.1997,24(11):2153-2157.
[35]Zavala F, Masson A, Hadaya K,et al. Granulocyte-colony stimulating factor treatment of lupus autoimmune disease in MRL-lpr/lpr mice. J Immunol.1999,163(9):5125-5132.
[36]Gottenberg JE, Roux S, Desmoulins F,et al. Granulocyte colony-stimulating factor therapy resulting in a flare of systemic lupus erythematosus:comment on the article by Yang and Hamilton. Arthritis Rheum.2001,44(10):2458-2460.
[37]Mills JA. Systemic lupus erythematosus. N Engl J Med.1994,330(26):1871-1879.
[38]Bombardier C, Gladman DD, Urowitz MB,et al. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum.1992,35(6):630-640.
[39]American College of Rheumatology Ad Hoc Committee on Systemic Lupus Erythematosus Response Criteria. The American College of Rheumatology response criteria for systemic lupus erythematosus clinical trials:measures of overall disease activity. Arthritis Rheum.2004,50(11):3418-3426.
[40]Leandro MJ, Edwards JC, Cambridge G,et al. An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis Rheum.2002 Oct;46(10):2673-7.
[41]Eisenberg R. SLE-Rituximab in lupus. Arthritis Res Ther.2003,5(4):157-159.
[42]Anolik JH, Barnard J, Cappione A,et al. Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus. Arthritis Rheum. 2004,50(11):3580-3590.
[43]Willis F, Marsh JC, Bevan DH,et al. The effect of treatment with Campath-1H in patients with autoimmune cytopenias. Br J Haematol.2001,114(4):891-898.
[44]Cohen Y, Polliack A, Nagler A. Treatment of refractory autoimmune diseases with ablative immunotherapy using monoclonal antibodies and/or high dose chemotherapy with hematopoietic stem cell support. Curr Pharm Des.2003;9(3):279-288.
[45]Talaulikar D, Tymms KE, Prosser I, et al.Autologous peripheral blood stem cell transplantation with in vivo T-cell depletion for life threatening refractory systemic lupus erythematosus.Lupus,2005,14(2):159-163.
[46]肖毅,刘文励.造血干细胞移植治疗系统性红斑狼疮进展.临床内科杂志,2004, 21(11)：790-792.
[47]Burt PK, Fassas A, Snowden J, et al. Collection of hematopoietic stem cells from patients with autoimmune diseases. Bone Marrow Transplant,2001,28(1):1-12.
[1]Shapiro E, Krivit W, Lockman L,et al. Long-term effect of bone-marrow transplantation for childhood-onset cerebral X-linked adrenoleukodystrophy. Lancet. 2000,356(9231):713-718.
[2]Moser H, Smith K,Watkins P, Powers J, Moser A. X-linked adrenoleukodystrophy. In:ScriverC, Beaudet A, Sly W, Valle D,eds.The Metabolic and Molecular Bases of Inherited Disease. Vol2. 8thed.NewYork,NY:McGraw-Hill;2001:3257-3301.
[3]Zhang P, Chen BJ, Chao NJ. Prevention of GVHD without losing GVL effect: windows of opportunity. Immunol Res.2011,49(1-3):49-55.
[4]Peters C, Charnas LR, Tan Y,et al. Cerebral X-linked adrenoleukodystrophy: the international hematopoietic cell transplantation experience from 1982 to 1999. Blood. 2004,104(3):881-888.
[5]Moser HW. Adrenoleukodystrophy: phenotype, genetics, pathogenesis and therapy. Brain.1997,120 (Pt 8):1485-1508.
[6]Kernan NA, Bartsch G, Ash RC, et al. Analysis of 462 transplantations from unrelated donors facilitated by the National Marrow Donor Program. N Engl J Med. 1993,328(9):593-602.
[7]Kapelushnik J, Varadi G, Nagler A. Matched unrelated human umbilical cord blood transplantation for X-linked adrenoleukodystrophy. J Pediatr Hematol Oncol. 1998,20(3):257-259.
[8]Moser H,Raymond G,Kohler W,Sokolowski P. Evaluation of the preventive effect of glyceryltri-oleate-trierucate (Lorenzo's Oil) therapy in X-linked adrenoleukodystrophy: results of two concurrenttrials. n:Roels F, Baes M,deBie S,eds. Peroxisomal Disorders and Regulation of Genes.New York,NY:KluwerPlenum;2003:369-387.
[9]Ito M, Blumberg BM, Mock DJ,et al. Potential environmental and host participants in the early white matter lesion of adreno-leukodystrophy:morphologic evidence for CD8 cytotoxic T cells, cytolysis of oligodendrocytes, and CD1-mediated lipid antigen presentation. J Neuropathol Exp Neurol.2001,60(10):1004-1019.
[1]Young NS. Acquired aplastic anemia. Ann Intern Med.2002,136(7):534-546.
[2]Young NS, Calado RT, Scheinberg P. Current concepts in the pathophysiology and treatment of aplastic anemia. Blood.2006,108(8):2509-2519.
[3]Young NS, Bacigalupo A, Marsh JC. Aplastic anemia:pathophysiology and treatment. Biol Blood Marrow Transplant.2010,16(1 Suppl):S119-125.
[4]Rosenfeld S, Follmann D, Nunez O,et al. Antithymocyte globulin and cyclosporine for severe aplastic anemia: association between hematologic response and long-term outcome. JAMA.2003,289(9):1130-1135.
[5]Scheinberg P, Wu CO, Nunez O,et al. Predicting response to immunosuppressive therapy and survival in severe aplastic anaemia. Br J Haematol.2009,144(2):206-216.
[6]Gupta V,Carreras J,Bajorunaite R,et al.Hematopoietic recovery and over all survival after HLA-matched sibling transplants for older patients with severe aplastic anemia.Blood.2008,112:2169.
[7]Marsh JC, Ball SE, Cavenagh J, Darbyshire P,et al. Guidelines for the diagnosis and management of aplastic anaemia. Br J Haematol.2009,147(1):43-70.
[8]Deeg HJ, O'Donnell M, Tolar J,et al. Optimization of conditioning for marrow transplantation from unrelated donors for patients with aplastic anemia after failure of immunosuppressive therapy. Blood.2006,108(5):1485-1491.
[9]World Marrow Donor Association Donor Registries Working Group. Stem cell donor registries annual report 2008.12th ed.Leiden:World Marrow Donor Association;2008.
[10]Lee SJ, Klein J, Haagenson M, Baxter-Lowe LA,et al. High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation. Blood. 2007,110(13):4576-4583.
[11]Horowitz MM. High-resolution typing for unrelated donor transplantation: how far do we go? Best Pract Res Clin Haematol.2009,22(4):537-541.
[12]Perez-Albuerne ED, Eapen M, Klein J, Gross TJ,et al. Outcome of unrelated donor stem cell transplantation for children with severe aplastic anemia. Br J Haematol. 2008,141(2):216-223.
[13]Viollier R, Socie G, Tichelli A,et al. Recent improvement in outcome of unrelated donor transplantation for aplastic anemia. Bone Marrow Transplant.2008,41(1):45-50.
[14]Schrezenmeier H, Passweg JR, Marsh JC,et al. Worse outcome and more chronic GVHD with peripheral blood progenitor cells than bone marrow in HLA-matched sibling donor transplants for young patients with severe acquired aplastic anemia. Blood. 2007,110(4):1397-1400.
[15]Eapen M, Rubinstein P, Zhang MJ,et al. Outcomes of transplantation of unrelated donor umbilical cord blood and bone marrow in children with acute leukaemia:a comparison study. Lancet.2007,369(9577):1947-1954.
[16]Eapen M, Rocha V, Sanz Qet al. Effect of graft source on unrelated donor haemopoietic stem-cell transplantation in adults with acute leukaemia: a retrospective analysis. Lancet Oncol.2010,11(7):653-660.
[17]MacMillan ML, Walters MC, Gluckman E. Transplant outcomes in bone marrow failure syndromes and hemoglobinopathies. Semin Hematol.2010,47(l):37-45.
[18]Chan KW, McDonald L, Lim D,et al. Unrelated cord blood transplantation in children with idiopathic severe aplastic anemia. Bone Marrow Transplant.2008,42(9):589-595.
[19]Yoshimi A, Kojima S, Taniguchi S,et al. Unrelated cord blood transplantation for severe aplastic anemia. Biol Blood Marrow Transplant.2008,14(9):1057-1063.
[20]Margolis DA, Casper JT. Alternative-donor hematopoietic stem-cell transplantation for severe aplastic anemia. Semin Hematol.2000,37(l):43-55.
[21]Storb R, Anasetti C, Appelbaum F,et al. Marrow transplantation for severe aplastic anemia and thalassemia major. Semin Hematol.1991,28(3):235-239.
[22]Socie G, Henry-Amar M, Bacigalupo A,et al. Malignant tumors occurring after treatment of aplastic anemia. European Bone Marrow Transplantation-Severe Aplastic Anaemia Working Party. N Engl J Med.1993,329(16):1152-1157.
[23]Deeg HJ, Socie G, Schoch G,et al. Malignancies after marrow transplantation for aplastic anemia and fanconi anemia: a joint Seattle and Paris analysis of results in 700 patients. Blood.1996,87(1):386-392.
[24]Kojima S, Matsuyama T, Kato S,et al. Outcome of 154 patients with severe aplastic anemia who received transplants from unrelated donors:the Japan Marrow Donor Program. Blood.2002,100(3):799-803.
[25]Bacigalupo A, Locatelli F, Lanino E,et al. Fludarabine, cyclophosphamide and anti-thymocyte globulin for alternative donor transplants in acquired severe aplastic anemia: a report from the EBMT-SAA Working Party. Bone Marrow Transplant. 2005,36(11):947-950.
[26]Bacigalupo A, Socie' G, Lanino E,et al. Fludarabine, cyclophosphamide, antithymocyte globulin, with or without low dose total body irradiation, for alternative donor transplants, in acquired severe aplastic anemia: a retrospective study from the EBMT-SAA working party. Haematologica.2010,95(6):976-982.
[27]Fraser CJ, Bhatia S, Ness K,et al. Impact of chronic graft-versus-host disease on the health status of hematopoietic cell transplantation survivors:a report from the Bone Marrow Transplant Survivor Study. Blood.2006,108(8):2867-2873.
[28]Rizzo JD, Curtis RE, Socie Qet al. Solid cancers after allogeneic hematopoietic cell transplantation. Blood.2009,113(5):1175-1183.
[2]Lu C, Braine HG, Kaizer H, et al. Preliminary results of high-dose busulfan and cyclophosphamide with syngeneic or autologous bone-marrow rescue. Cancer Treat Rep. 1984,68(5):711-717.
[3]Tutschka PJ, Copelan EA, Klein JP. Bone marrow transplantation for leukemia following a new busulfan and cyclophosphamide regimen. Blood.1987,70(5):1382-1388.
[4]McDonald GB, Sharma P, Matthews DE,et al. The clinical course of 53 patients with venocclusive disease of the liver after marrow transplantation. Transplantation. 1985,39(6):603-608.
[5]Benet LZ,Sheiner LB.Pharmacokinetics:the dynamics of drug absorption, distribution, andelimi-nation. In:Goodman Gilman A,Goodman LS, Rall TW, Murad F,eds.Goodman and Gilman,s the Pharmacological Basis of Therapeutics.7thed. NewYork,NY:MacMillan; 1985:8.
[6]Bhagwatwar HP, Phadungpojna S, Chow DS, et al. Formulation and stability of busulfan for intravenous administration in high-dose chemotherapy. Cancer Chemother Pharmacol.1996,37(5):401-408.
[7]Andersson BS, Kashyap A, Gian V, et al. Conditioning therapy with intravenous busulfan and cyclophosphamide (IV BuCy2) for hematologic malignancies prior to allogeneic stem cell transplantation: a phase Ⅱ study. Biol Blood Marrow Transplant. 2002,8(3):145-154.
[8]Kashyap A, Wingard J, Cagnoni P, et al. Intravenous versus oral busulfan as part of a busulfan/cyclophosphamide preparative regimen for allogeneic hematopoietic stem cell transplantation: decreased incidence of hepatic venoocclusive disease (HVOD), HVOD-related mortality, and overall 100-day mortality. Biol Blood Marrow Transplant. 2002,8(9):493-500.
[9]Grochow LB, Noe DA, Ettinger DS, et al. A phase I trial of trimetrexate glucuronate (NSC 352122) given every 3 weeks:clinical pharmacology and pharmacodynamics. Cancer Chemother Pharmacol.1989,24(5):314-320.
[10]Grochow LB. Busulfan disposition: the role of therapeutic monitoring in bone marrow transplantation induction regimens. Semin Oncol.1993,20(4 Suppl 4):18-25.
[11]Hassan M, Oberg G, Ehrsson H, et al. Pharmacokinetic and metabolic studies of high-dose busulphan in adults. Eur J Clin Pharmacol.1989,36(5):525-530.
[12]Vassal G, Deroussent A, Hartmann O, et al. Dose-dependent neurotoxicity of high-dose busulfan in children: a clinical and pharmacological study. Cancer Res. 1990,50(19):6203-6207.
[13]Slattery JT, Sanders JE, Buckner CD, et al. Graft-rejection and toxicity following bone marrow transplantation in relation to busulfan pharmacokinetics. Bone Marrow Transplant. 1995,16(1):31-342.
[14]Andersson BS, Thall PF, Madden T, et al. Busulfan systemic exposure relative to regimen-related toxicity and acute graft-versus-host disease:defining a therapeutic window for i.v. BuCy2 in chronic myelogenous leukemia. Biol Blood Marrow Transplant. 2002,8(9):477-485.
[15]Russell JA, Tran HT, Quinlan D, et al. Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes. Biol Blood Marrow Transplant. 2002,8(9):468-476.
[16]Ryu SG, Lee JH, Choi SG, et al. Randomized comparison of four-times-daily versus once-daily intravenous busulfan in conditioning therapy for hematopoietic cell transplantation. Biol Blood Marrow Transplant,2007,13(9):1095-1105.
[17]Zhang P, Chen BJ, Chao NJ. Prevention of GVHD without losing GVL effect: windows of opportunity. Immunol Res.2011,49(1-3):49-55.
[18]肖毅,张东华,黄伟,等.造血干细胞移植治疗血液病及实体瘤的疗效分析.华中科技大学学报(医学版),2006,35(5)：644-652.
[19]Fisher VL, Barnes YJ, Nuss SL. Pretransplant conditioning in adults and children: dose assurance with intravenous busulfan. Oncol Nurs Forum.2006,33(2):E36-43.
[20]Kaplan EL,Meier P.Nonparametric estimation From incomplete observations.J Am Stat Assoc.1958,53:457-481.
[21]Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep.1966,50(3):163-170.
[22]Cox DR. Regression models and life tables (with discussion).J R Stat Soc B.1972,34:187-220.
[23]Therneau TM, Grambsch P. Modeling Survival Data.New York,NY: Springer;2000.
[24]Cleveland, WS:Robust locally-weighted regression and smoothing scatterplots.J Am Stat Assoc.1979,74:829-836.
[25]Therneau TM, Grambsch P. Modeling Survival Data:Extending the Cox Model. Chap.3.7.New York,NY:Springer;2000,68-77.
[26]Congdon P.Bayesian Statistical Modeling.New York,NY:Wiley;2001.
[27]Venables WN,Ripley BD.Modern Applied Statistics With Splus.3rded. NewYork, NY: Springer; 1999.
[28]Therneau TM: A package for survival analysis in S. Rochester, MN:Mayo Clinic Foundation,1997.
[29]Andersson BS, Madden T, Tran HT, et al. Acute safety and pharmacokinetics of intravenous busulfan when used with oral busulfan and cyclophosphamide as pretransplantation conditioning therapy: a phase I study. Biol Blood Marrow Transplant. 2000,6(5A):548-554.
[30]Gibaldi M, Perrier D.Pharmacokinetics. 2nd ed.New York, NY:Marcel Dekker;1982:409-417.
[31]D'Argenio DZ,Schumitzky A.ADAPT II User's Guide:Pharmacokinetic/ Pharmacodynamic Systems Analysis Software. LosAngeles,CA:Biomedical Simulations Resource; 1997.
[32]Hassan M, Nilsson C, Hassan Z, et al.A phase II trial of liposomal busulphan as an intravenous myeloablative agent prior to stem cell transplantation: 500 mg/m(2) as a optimal total dose for conditioning.Bone Marrow Transplant.2002,30(12):833-841.
[33]Deeg HJ, Storer B, Slattery JT, et al. Conditioning with targeted busulfan and cyclophosphamide for hemopoietic stem cell transplantation from related and unrelated donors in patients with myelodysplastic syndrome. Blood.2002,100(4):1201-1207.
[34]Thall PF, Champlin RE, Andersson BS. Comparison of 100-day mortality rates associated with i.v. busulfan and cyclophosphamide vs other preparative regimens in allogeneic bone marrow transplantation for chronic myelogenous leukemia:Bayesian sensitivity analyses of confounded treatment and center effects. Bone Marrow Transplant. 2004,(12):1191-1199.
[35]Kashyap A, Wingard J, Cagnoni P, et al.Intravenous versus oral busulfan as part of a busulfan/cyclophosphamide preparative regimen for allogeneic hematopoietic stem cell transplantation: decreased incidence of hepatic venoocclusive disease (HVOD), HVOD-related mortality, and overall 100-day mortality.Biol Blood Marrow Transplant. 2002,8(9):493-500.
[36]肖毅,张义成,张东华,等.采用静脉注射白消安预处理方案的异基因造血干细胞移植治疗恶性血液病一例.中华器官移植杂志.2006,27(11)：695-697.
[37]Small TN, Young JW, Castro-Malaspina H, et al. Intravenous busulfan and melphalan, tacrolimus, and short-course methotrexate followed by unmodified HLA-matched related or unrelated hematopoietic stem cell transplantation for the treatment of advanced hematologic malignancies. Biol Blood Marrow Transplant.2007,13(2):235-244.
[38]Andersson BS, Kashyap A, Gian V, et al.Conditioning therapy with intravenous busulfan and cyclophosphamide (IV BuCy2) for hematologic malignancies prior to allogeneic stem cell transplantation: a phase Ⅱ study. Biol Blood Marrow Transplant.2002, 8(3):145-154.
[39]Grochow LB. Parenteral busulfan:is therapeutic monitoring still warranted? Biol Blood Marrow Transplant.2002,8(9):465-467.
[40]Cho YH, Lim HA, Lee MH, et al. Pharmacokinetics and.tolerability of intravenous busulfan in hematopoietic stem cell transplantation. Clin Transplant.2007,21 (3):417-422.
[41]Ringden O, Labopin M, Tura S, et al.A comparison of busulphan versus total body irradiation combined with cyclophosphamide as conditioning for autograft or allograft bone marrow transplantation in patients with acute leukaemia. Acute Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT).Br J Haematol. 1996,93(3):637-645.
[42]Kim SE, Lee JH, Choi SJ, et al. Morbidity and non-relapse mortality after allogeneic bone marrow transplantation in adult leukemia patients conditioned with busulfan plus cyclophosphamide:a retrospective comparison of oral versus intravenous busulfan. Haematologica.2005,90(2):285-286.
[43]童秀珍,许多荣,邹外一,等.静脉剂型白消安为主的预处理方案对接受异基因造血干细胞移植的白血病患者的疗效及相关毒性.癌症.2007,26(8)：914-918.
[44]Andersson BS, Madden T, Tran HT, et al.Acute safety and pharmacokinetics of intravenous busulfan when used with oral busulfan and cyclophosphamide as pretransplantation conditioning therapy: a phase I study. Biol Blood Marrow Transplant. 2000,6(5):548-554.
[45]Lee JH, Choi SJ, Lee JH, et al. Decreased incidence of hepatic veno-occlusive disease and fewer hemostatic derangements associated with intravenous busulfan vs oral busulfan in adults conditioned with busulfan + cyclophosphamide for allogeneic bone marrow transplantation. Ann Hematol.2005,84(5):321-330.
[46]Shimoni A, Bielorai B, Toren A, et al. Intravenous busulfan-based conditioning prior to allogeneic hematopoietic stem cell transplantation: myeloablation with reduced toxicity. Exp Hematol.2003,31(5):428-434.
[47]Aggarwal C, Gupta S, Vaughan WP, et al. Improved outcomes in intermediate- and high-risk aggressive non-Hodgkin lymphoma after autologous hematopoietic stem cell transplantation substituting intravenous for oral busulfan in a busulfan, cyclophosphamide, and etoposide preparative regimen. Biol Blood Marrow Transplant.2006,12(7):770-777.
[48]Hoy SM, Lyseng-Williamson KA. Intravenous busulfan:in the conditioning treatment of pediatric patients prior to hematopoietic stem cell transplantation. Paediatr Drugs.2007, 9(4):271-278.
[49]Lee MY, Chiou TJ, Bai LY, et al.Intravenous busulfan as preparative regimen in pediatric patients receiving hematopoietic stem cell transplantation: the preliminary experience in Taiwan. J Chin Med Assoc.2004,67(3):117-122.
[50]Kletzel M, Jacobsohn D, Duerst R. Pharmacokinetics of a test dose of intravenous busulfan guide dose modifications to achieve an optimal area under the curve of a single daily dose of intravenous busulfan in children undergoing a reduced-intensity conditioning regimen with hematopoietic stem cell transplantation. Biol Blood Marrow Transplant, 2006,12(4):472-479.
[51]Dalle JH, Wall D, Theoret Y, et al. Intravenous busulfan for allogeneic hematopoietic stem cell transplantation in infants:clinical and pharmacokinetic results. Bone Marrow Transplant.2003,32(7):647-651.
[52]Vaughan WP,Cagnoni P,Fernandez H,etal.De-Creased incidence of and risk factors for hepatic veno-occlusive disease with an intravenous busulfan(BU) containing preparative regimen for hematopoietic stem cell transplantation(HSCT) [abstract].Blood.1998,92:516a.
[53]McDonald GB, Slattery JT, Bouvier ME, et al. Cyclophosphamide metabolism, liver toxicity, and mortality following hematopoietic stem cell transplantation. Blood. 2003,101(5):2043-2048.
[54]Gandhi V, Plunkett W. Cellular and clinical pharmacology of fludarabine. Clin Pharmacokinet.2002,41(2):93-103.
[55]de Lima M, Couriel D, Thall PF, et al. Once-daily intravenous busulfan and fludarabine:clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS. Blood. 2004,104(3):857-864.
[56]Bornhauser M, Storer B, Slattery JT, et al.Conditioning with fudarabine and targeted busulfan for tansplantation of allogeneic hematopoietic stem cells. Blood. 2003,102:820-826.
[57]Dix SP, Wingard JR, Mullins RE, et al. Association of busulfan area under the curve with veno-occlusive disease following BMT. Bone Marrow Transplant. 1996,17(2):225-230.
[58]Madden T, Nguyen J, Thapar N, et al. Thepharmacokinetics (PK) of once daily intravenous busulfan(Bu) aspart of pretransplant preparative regimens; a comparison to Q 6 hourly dosing [abstract].Blood.2003,102:477a.
[59]Blume KG, Kopecky KJ, Henslee-Downey JP, et al. A prospective randomized comparison of total body irradiation-etoposide versus busulfan-cyclophosphamide as preparatory regimens for bone marrow transplantation in patients with leukemia who were not in first remission: a Southwest Oncology Group study. Blood.1993,81(8):2187-2193.
[60]Gupta V, Lazarus HM, Keating A. Myeloablative conditioning regimens for AML allografts:30 years later. Bone Marrow Transplant.2003,32(10):969-978.
[61]Thomas ED, Buckner CD, Banaji M, et al. One hundred patients with acute leukemia treated by chemotherapy, total body irradiation, and allogeneic marrow transplantation. Blood.1977,49(4):511-533.
[62]Estey E, deLima M, Strom S, et al. Long-term follow-up of patients with newly diagnosed acute myeloid leukemia treated at the University of Texas M.D. Anderson Cancer Center. Cancer.1997,80(11 Suppl);2176-2180.
[1]Marsh JC, Ball SE, Darbyshire P,et al. Guidelines for the diagnosis and management of acquired aplastic anaemia. Br J Haematol.2003,123(5):782-801.
[2]George ER, Storb R. Allogeneic Hematopoietic Cell Transplantation for Aplastic Anemia. In:Blume KG, Forman SJ, Thomas ED, editors. Thomas'O Hematopoietic Cell Transplantation. Boston:Blackwell;2004. p.981-1001.
[3]Bacigalupo A,. Hows J, Gluckman E,et al. Bone marrow transplantation (BMT) versus immunosuppression for the treatment of severe aplastic anaemia (SAA):a report of the EBMT SAA working party. Br J Haematol.1988,70(2):177-182.
[4]Doney K, Leisenring W, Storb R,et al. Primary treatment of acquired aplastic anemia: outcomes with bone marrow transplantation and immunosuppressive therapy. Seattle Bone Marrow Transplant Team. Ann Intern Med.1997,126(2):107-115.
[5]Passweg JR, Socie G, Hinterberger W,et al. Bone marrow transplantation for severe aplastic anemia: has outcome improved? Blood.1997,90(2):858-864.
[6]Bacigalupo A, Brand R, Oneto R,et al. Treatment of acquired severe aplastic anemia: bone marrow transplantation compared with immunosuppressive therapy--The European Group for Blood and Marrow Transplantation experience. Semin Hematol. 2000,37(1):69-80.
[7]Ades L, Mary JY, Robin M,et al. Long-term outcome after bone marrow transplantation for severe aplastic anemia. Blood.2004,103(7):2490-2497.
[8]Storb R, Etzioni R, Anasetti C et al. Cyclophosphamide combined with antithymocyte globulin in preparation for allogeneic marrow transplants in patients with aplastic anemia.Blood,1994,84:941-949.
[9]Georges GE, Storb R. Allogeneic hematopoietic cell transplantation for aplastic anemia. In: Blume KG, Forman SJ, AppelbaumFR (eds) Thomas' Hematopoietic Cell Transplantation.Blackwell Publishing Ltd: Oxford,2004:981-1001.
[10]Deeg HJ, Anasetti C, Petersdorf E et al. Cyclophosphamide plus ATG conditioning is insuf.cient for sustained hematopoietic reconstitution in patients with severe aplastic anemia transplanted with marrow from HLA-A, B, DRB matchedunrelated donors. Blood,1994,83:3417-3418.
[11]Young NS, Calado RT, Scheinberg P. Current concepts in the pathophysiology and treatment of aplastic anemia. Blood.2006,108(8):2509-2519.
[12]Marsh JC. Treatment of acquired aplastic anemia. Haematologica.2007,92(l):2-5.
[13]Ringden O, Remberger M, Svenberg P, et al. Fludarabine-based disease-specific conditioning or conventional myeloablative conditioning in hematopoietic stem cell transplantation for treatment of non-malignant diseases. Bone Marrow Transplant. 2007,39(7):383-388.
[14]Kumar R, Prem S, Mahapatra M, et al. Fludarabine, cyclophosphamide and horse antithymocyte globulin conditioning regimen for allogeneic peripheral blood stem cell transplantation performed in non-HEPA filter rooms for multiply transfused patients with severe aplastic anemia.B one Marrow Transplant.2006,37(8):745-749.
[15]Itala M, Aho H, Remes K. Reduced-intensity conditioning and blood stem cell transplantation from an HLA-identical sibling for severe aplastic anaemia:two patients with successful engraftment but a fatal post-transplant lymphoproliferative disorder in the other. Hematol J.2004,5(5):440-443.
[16]Srinivasan R, Takahashi Y, McCoy JP,et al. Overcoming graft rejection in heavily transfused and allo-immunised patients with bone marrow failure syndromes using fludarabine-based haematopoietic cell transplantation. Br J Haematol. 2006,133(3):305-314.
[17]Resnick IB, Aker M, Shapira MY,et al. Allogeneic stem cell transplantation for severe acquired aplastic anaemia using a fludarabine-based preparative regimen. Br J Haematol. 2006,133(6):649-654.
[18]Gomez-Almaguer D, Vela-Ojeda J, Jaime-Perez JC,et al. Allografting in patients with severe, refractory aplastic anemia using peripheral blood stem cells and a fludarabine-based conditioning regimen: the Mexican experience. Am J Hematol.2006,81(3):157-161.
[19]George B, Mathews V, Viswabandya A,et al. Fludarabine and cyclophosphamide based reduced intensity conditioning (RIC) regimens reduce rejection and improve outcome in Indian patients undergoing allogeneic stem cell transplantation for severe aplastic anemia. Bone Marrow Transplant.2007,40(1):13-18.
[20]Bacigalupo A, Locatelli F, Lanino E,et al. Fludarabine, cyclophosphamide and anti-thymocyte globulin for alternative donor transplants in acquired severe aplastic anemia: a report from the EBMT-SAA Working Party. Bone Marrow Transplant. 2005,36(11):947-950.
[21]Maury S, Bacigalupo A, Anderlini P,et al. Improved outcome of patients older than 30 years receiving HLA-identical sibling hematopoietic stem cell transplantation for severe acquired aplastic anemia using fludarabine-based conditioning: a comparison with conventional conditioning regimen. Haematologica.2009,94(9):1312-1315.
[22]Zhang P, Chen BJ, Chao NJ. Prevention of GVHD without losing GVL effect: windows of opportunity. Immunol Res.2011,49(1-3):49-55.
[23]Ahn MJ, Choi JH, Lee YY, et al. Outcome of adult severe or very severe aplastic anemia treated with immunosuppressive therapy compared with bone marrow transplantation: multicenter trial. Int J Hematol,2003,78:133-138.
[24]Kanda Y, Chiba S, Hirai H, et al. Allogeneic hematopoietic stem cell transplantation from family members other than HLA-identical siblings over the last decade (1991-2000). Blood,2003,102(4):1541-1547.
[25]Davies SM, Wagner JN, Defor T, et al. Unrelated donor bone marrow transplantation for children and adolesents with aplastic anemia or myelodysplasia. Br J Haematol,1997,96(7):749-756.
[26]Margolis DA, Casper JT. Alternative-donor hematopoietic stem-cell transplantation for severe aplastic anemia. Semin Hematol.2000 Jan;37(1):43-55.
[27]Storb R, Anasetti C, Appelbaum F,et al. Marrow transplantation for severe aplastic anemia and thalassemia major. Semin Hematol.1991,28(3):235-239.
[28]Socie G, Henry-Amar M, Bacigalupo A,et al. Malignant tumors occurring after treatment of aplastic anemia. European Bone Marrow Transplantation-Severe Aplastic Anaemia Working Party. N Engl J Med.1993,329(16):1152-1157.
[29]Deeg HJ, Socie G, Schoch G,et al. Malignancies after marrow transplantation for aplastic anemia and fanconi anemia:a joint Seattle and Paris analysis of results in 700 patients. Blood.1996,87(1):386-392.
[30]Deeg HJ, O'Donnell M, Tolar J,et al. Optimization of conditioning for marrow transplantation from unrelated donors for patients with aplastic anemia after failure of immunosuppressive therapy. Blood.2006,108(5):1485-1491.
[31]Perez-Albuerne ED, Eapen M, Klein J, Gross TJ,et al. Outcome of unrelated donor stem cell transplantation for children with severe aplastic anemia. Br J Haematol. 2008,141(2):216-223.
[32]Kojima S, Matsuyama T, Kato S,et al. Outcome of 154 patients with severe aplastic anemia who received transplants from unrelated donors:the Japan Marrow Donor Program. Blood:2002,100(3):799-803.
[33]Bacigalupo A, Locatelli F, Lanino E,et al. Fludarabine, cyclophosphamide and anti-thymocyte globulin for alternative donor transplants in acquired severe aplastic anemia: a report from the EBMT-SAA Working Party. Bone Marrow Transplant. 2005,36(11):947-950.
[34]Bacigalupo A, Socie'G, Lanino E,et al. Fludarabine, cyclophosphamide, antithymocyte globulin, with or without low dose total body irradiation, for alternative donor transplants, in acquired severe aplastic anemia: a retrospective study from the EBMT-SAA working party. Haematologica.2010,95(6):976-982.
[35]Chan KW, McDonald L, Lim D,et al. Unrelated cord blood transplantation in children with idiopathic severe aplastic anemia. Bone Marrow Transplant.2008,42(9):589-595.
[36]Eapen M, Rubinstein P, Zhang MJ,et al. Outcomes of transplantation of unrelated donor umbilical cord blood and bone marrow in children with acute leukaemia:a comparison study. Lancet.2007,369(9577):1947-1954.
[37]Eapen M, Rocha V, Sanz G,et al. Effect of graft source on unrelated donor haemopoietic stem-cell transplantation in adults with acute leukaemia: a retrospective analysis. Lancet Oncol.2010,11(7):653-660.
[38]MacMillan ML, Walters MC, Gluckman E. Transplant outcomes in bone marrow failure syndromes and hemoglobinopathies. Semin Hematol.2010,47(l):37-45.
[39]Chan KW, McDonald L, Lim D,et al. Unrelated cord blood transplantation in children with idiopathic severe aplastic anemia. Bone Marrow Transplant.2008,42(9):589-595.
[40]Yoshimi A, Kojima S, Taniguchi S,et al. Unrelated cord blood transplantation for severe aplastic anemia. Biol Blood Marrow Transplant.2008,14(9):1057-1063.
[41]Deeg HJ, Amylon ID, Harris RE et al. Marrow transplants fromunrelated donors for patients with aplastic anemia: minimum effective dose of total body irradiation. Biol Blood Marrow Transplant,2001,7:208-215.
[42]Kojima S, Inaba J, Yoshimi A et al. Unrelated donor marrow transplantation in children with severe aplastic anaemia using cyclophosphamide, anti-thymocyte globulin and total body irradiation. Br J Haematol,2001,114:706-711.
[43]Vassiliou GS, Webb DK, Pamphilon D et al. Improved outcome of alternative donor bone marrow transplantation in children with severe aplastic anaemia using a conditioning regimen containing low-dose total body irradiation, cyclophosphamide and Campath. Br J Haematol,2001,114:701-705.
[44]Socie G, Henry-Amar M, Cosset JM et al. Increased incidence of solid malignant tumors after bone marrow transplantation for severe aplastic anemia. Blood,1991,78: 277-279.
[45]Bacigalupo A, Locatelli F, Lanino E, et al. Fludarabine, cyclophosphamide and anti-thymocyte globulin for alternative donor transplants in acquired severe aplastic anemia: a report from the EBMT-SAA Working Party. Bone Marrow Transplant.2005, 35:1655-1661.
[46]Urban C, Benesch M, Sykora KW, et al. Non-radiotherapy conditioning with stem cell transplantation from alternative donors in children with refractory severe aplastic anemia. Bone Marrow Transplant,2005,35:591-594.
[47]Ambulkar I, Parikh PM, Saikia T. Successful allogeneic stem cell transplantation with fludarabine-based conditioning regimen in severe aplastic anemia. J Assoc Physicians India, 2003,51:715-716.
[48]Lee JH, Choi SJ, Lee JH, et al. Non-total body irradiation containing preparative regimen in alternative donor bone marrow transplantation for severe aplastic anemia. Bone Marrow Transplant.2005,35:755-761.
[49]Bornhauser M, schuler U, Porksen G, et al. Mycophenolate mofetil and cyclosporine as graft-versus-host disease prophylax is after allogeneic blood stem cell transplantation. Transplantstion,1999,67:499-504.
[50]黄河,林茂芳,孟海涛,等.霉酚酸酣联合CsA和短程MTX预防非亲缘异基因骨做移植的急性移植物抗宿主病.中华血液学杂志,2001,22：76-78.
[51]Basara N, Kiehl MG, Blau W, et al. Mycophenolate Mofetil in the treatment of acute and chronic GVHD in hematopoitic stem cell transplant patients:four years of experience. Transplant Proc,2001,33:2121-2133.
[52]Champlin RE, Perez WS, Passweg JR,et al. Bone marrow transplantation for severe aplastic anemia: a randomized controlled study of conditioning regimens. Blood. 2007,109(10):4582-4585.
[53]Casado LF, Steegmann JL, Pico M,et al. Study of chimerism in long-term survivors after bone marrow transplantation for severe acquired aplastic anemia. Bone Marrow Transplant.1996,18(2):405-409.
[1]Abu-Shakra M, Urowitz MB, Gladman DD,et al. Mortality studies in systemic lupus erythematosus. Results from a single center. II. Predictor variables for mortality. J Rheumatol.1995,22(7):1265-1270.
[2]Cervera R, Khamashta MA, Font J,et al. Morbidity and mortality in systemic lupus erythematosus during a 5-year period. A multicenter prospective study of 1,000 patients. European Working Party on Systemic Lupus Erythematosus. Medicine (Baltimore). 1999,78(3):167-175.
[3]Austin HA 3rd, Klippel JH, Balow JE,et al. Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. N Engl J Med.1986,314(10):614-619.
[4]Bansal VK, Beto JA. Treatment of lupus nephritis:a meta-analysis of clinical trials. Am J Kidney Dis.1997,29(2):193-199.
[5]Chan TM, Li FK, Tang CS,et al. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group. N Engl J Med.2000,343(16):1156-1162.
[6} Takada K, Illei GG, Boumpas DT. Cyclophosphamide for the treatment of systemic lupus erythematosus. Lupus.2001,10(3):154-161.
[7]Alaez C, Loyola M, Murguia A, et al. Hematopoietic stem cell transplantation (HSCT): an approach to autoimmunity.Autoimmun Rev,2006,5(3):167-179.
[8]Burt RK, Verda L, Oyama Y, et al. Non-myeloablative stem cell transplantation for autoimmune diseases. Springer Semin Immunopathol.2004,26(1-2):57-69.
[9]Ikehara S, Good RA, Nakamura T,et al. Rationale for bone marrow transplantation in the treatment of autoimmune diseases. Proc Natl Acad Sci U S A.1985,82(8):2483-2487.
[10]Snowden JA, Brooks PM, Biggs JC. Haemopoietic stem cell transplantation for autoimmune diseases. Br J Haematol.1997,99(1):9-22.
[11]Burt RK, Slavin S,Burns WH,et al. Induction of tolerance in autoimmune diseases by hematopoietic stem cell transplantation:getting closer to a cure? Blood. 2002,99(3):768-784.
[12]Marmont AM. Stem cell transplantation for severe autoimmune diseases:progress and problems. Haematologica.1998,83(8):733-743.
[13]Burt RK, Traynor A, Ramsey-Goldman R. Hematopoietic stem-cell transplantation for systemic lupus erythematosus. N Engl J Med.1997,337(24):1777-1778.
[14]Burt RK, Traynor AE, Pope R,et al. Treatment of autoimmune disease by intense immunosuppressive conditioning and autologous hematopoietic stem cell transplantation. Blood.1998,92(10):3505-3514.
[15]Traynor AE, Schroeder J, Rosa RM,et al. Treatment of severe systemic lupus erythematosus with high-dose chemotherapy and haemopoietic stem-cell transplantation: a phase I study. Lancet.2000,356(9231):701-707.
[16]Traynor AE, Barr WG, Rosa RM,et al. Hematopoietic stem cell transplantation for severe and refractory lupus. Analysis after five years and fifteen patients. Lancet. 2000,356(9231):701-707.
[17]Raetz E, Beatty PG, Adams RH. Treatment of severe Evans syndrome with an allogeneic cord blood transplant. Bone Marrow Transplant,1997,20(5):427-429.
[18]Musso M, Porretto F, Crescimanno A, et al. Autologous peripheral blood stem and progenitor (CD34+) cell transplantation for systemic lupus erythematosus complicated by Evans syndrome. Lupus,1998,7(7):492-494.
[19]Paillard C, Kanold J, Halle P, et al. Two-step immunoablative treatment with autologous peripheral blood CD34(+) cell transplantation in an 8-year-old boy with autoimmune haemolytic anaemia. Br J Haematol,2000,110(4):900-902.
[20]Jindra P, Koza V, Fiser J, et al. Autologous CD34+ cells transplantation after FAMP treatment in a patient with CLL and persisting AIHA:complete remission of lymphoma with control of autoimmune complications. Bone Marrow Transplant,1999,24(2):215-217.
[21]Treon SP, Anderson KC. The use of rituximab in the treatment of malignant and nonmalignant plasma cell disorders. Semin Oncol,2000,27(6 suppl 2):79-85.
[22]Zecca M, Nobili B, Ramenghi U. Rituximab for the treatment of refractory autoimmune hemolytic anemia in children. Blood,2003,101(10):3857-3861.
[23]Hongeng S, Tardtong P, Worapongpaiboon S, et al. Successful treatment of refractory autoimmune haemolytic anaemia in a post-unrelated bone marrow transplant paediatric patient with rituximab. Bone Marrow Transplant,2002,29(10):871-872.
[24]Raj A, Bertolone S, Cheerva A, et al. Successful treatment of refractory autoimmune hemolytic anemia with monthly rituximab following nonmyeloablative stem cell transplantation for sickle cell disease. J Pediatr Hematol Oncol,2004,26(5):312-314.
[25]Endo T, Nakao S, Koizumi K, et al. Successful treatment with rituximab for autoimmune hemolytic anemia concomitant with proliferation of Epstein-Barr virus and monoclonal gammopathy in a post-nonmyeloablative stem cell transplant patient. Ann Hematol,2004,83(2):114-116.
[26]Seeliger S, Baumann M, Mohr M, et al. Autologous peripheral blood stem cell transplantation and anti-B-cell directed immunotherapy for refractory auto-immune haemolytic anaemia. Eur J Pediatr,2001,160(8):492-496.
[27]Burt RK, Traynor A, Statkute L, et al.Nonmyeloablative hematopoietic stem cell transplantation for systemic lupus erythematosus.JAMA,2006,295(5):527-535.
[28]Jayne D, Passweg J, Marmont A,et al. Autologous stem cell transplantation for systemic lupus erythematosus. Lupus.2004;13(3):168-176.
[29]Statkute L, Traynor A, Oyama Y,et al. Antiphospholipid syndrome in patients with systemic lupus erythematosus treated by autologous hematopoietic stem cell transplantation. Blood.2005,106(8):2700-2709.
[30]Dubey S, Nityanand S. Involvement of Fas and TNF pathways in the induction of apoptosis of T cells by antithymocyte globulin. Ann Hematol.2003 Aug;82(8):496-9.
[31]Young N, Speck B. Antithymocyte and antilymphocyte globulins:clinical trials and mechanism of action. Prog Clin Biol Res.1984,148:221-226.
[32]Kang I, Park SH. Infectious complications in SLE after immunosuppressive therapies. Curr Opin Rheumatol.2003,15(5):528-534.
[33]Salzberger B, Bowden RA, Hackman RC,et al. Neutropenia in allogeneic marrow transplant recipients receiving ganciclovir for prevention of cytomegalovirus disease: risk factors and outcome. Blood.1997,90(6):2502-2508.
[34]Euler HH, Harten P, Zeuner RA,et al. Recombinant human granulocyte colony stimulating factor in patients with systemic lupus erythematosus associated neutropenia and refractory infections. J Rheumatol.1997,24(11):2153-2157.
[35]Zavala F, Masson A, Hadaya K,et al. Granulocyte-colony stimulating factor treatment of lupus autoimmune disease in MRL-lpr/lpr mice. J Immunol.1999,163(9):5125-5132.
[36]Gottenberg JE, Roux S, Desmoulins F,et al. Granulocyte colony-stimulating factor therapy resulting in a flare of systemic lupus erythematosus:comment on the article by Yang and Hamilton. Arthritis Rheum.2001,44(10):2458-2460.
[37]Mills JA. Systemic lupus erythematosus. N Engl J Med.1994,330(26):1871-1879.
[38]Bombardier C, Gladman DD, Urowitz MB,et al. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum.1992,35(6):630-640.
[39]American College of Rheumatology Ad Hoc Committee on Systemic Lupus Erythematosus Response Criteria. The American College of Rheumatology response criteria for systemic lupus erythematosus clinical trials:measures of overall disease activity. Arthritis Rheum.2004,50(11):3418-3426.
[40]Leandro MJ, Edwards JC, Cambridge G,et al. An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis Rheum.2002 Oct;46(10):2673-7.
[41]Eisenberg R. SLE-Rituximab in lupus. Arthritis Res Ther.2003,5(4):157-159.
[42]Anolik JH, Barnard J, Cappione A,et al. Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus. Arthritis Rheum. 2004,50(11):3580-3590.
[43]Willis F, Marsh JC, Bevan DH,et al. The effect of treatment with Campath-1H in patients with autoimmune cytopenias. Br J Haematol.2001,114(4):891-898.
[44]Cohen Y, Polliack A, Nagler A. Treatment of refractory autoimmune diseases with ablative immunotherapy using monoclonal antibodies and/or high dose chemotherapy with hematopoietic stem cell support. Curr Pharm Des.2003;9(3):279-288.
[45]Talaulikar D, Tymms KE, Prosser I, et al.Autologous peripheral blood stem cell transplantation with in vivo T-cell depletion for life threatening refractory systemic lupus erythematosus.Lupus,2005,14(2):159-163.
[46]肖毅,刘文励.造血干细胞移植治疗系统性红斑狼疮进展.临床内科杂志,2004, 21(11)：790-792.
[47]Burt PK, Fassas A, Snowden J, et al. Collection of hematopoietic stem cells from patients with autoimmune diseases. Bone Marrow Transplant,2001,28(1):1-12.
[1]Shapiro E, Krivit W, Lockman L,et al. Long-term effect of bone-marrow transplantation for childhood-onset cerebral X-linked adrenoleukodystrophy. Lancet. 2000,356(9231):713-718.
[2]Moser H, Smith K,Watkins P, Powers J, Moser A. X-linked adrenoleukodystrophy. In:ScriverC, Beaudet A, Sly W, Valle D,eds.The Metabolic and Molecular Bases of Inherited Disease. Vol2. 8thed.NewYork,NY:McGraw-Hill;2001:3257-3301.
[3]Zhang P, Chen BJ, Chao NJ. Prevention of GVHD without losing GVL effect: windows of opportunity. Immunol Res.2011,49(1-3):49-55.
[4]Peters C, Charnas LR, Tan Y,et al. Cerebral X-linked adrenoleukodystrophy: the international hematopoietic cell transplantation experience from 1982 to 1999. Blood. 2004,104(3):881-888.
[5]Moser HW. Adrenoleukodystrophy: phenotype, genetics, pathogenesis and therapy. Brain.1997,120 (Pt 8):1485-1508.
[6]Kernan NA, Bartsch G, Ash RC, et al. Analysis of 462 transplantations from unrelated donors facilitated by the National Marrow Donor Program. N Engl J Med. 1993,328(9):593-602.
[7]Kapelushnik J, Varadi G, Nagler A. Matched unrelated human umbilical cord blood transplantation for X-linked adrenoleukodystrophy. J Pediatr Hematol Oncol. 1998,20(3):257-259.
[8]Moser H,Raymond G,Kohler W,Sokolowski P. Evaluation of the preventive effect of glyceryltri-oleate-trierucate (Lorenzo's Oil) therapy in X-linked adrenoleukodystrophy: results of two concurrenttrials. n:Roels F, Baes M,deBie S,eds. Peroxisomal Disorders and Regulation of Genes.New York,NY:KluwerPlenum;2003:369-387.
[9]Ito M, Blumberg BM, Mock DJ,et al. Potential environmental and host participants in the early white matter lesion of adreno-leukodystrophy:morphologic evidence for CD8 cytotoxic T cells, cytolysis of oligodendrocytes, and CD1-mediated lipid antigen presentation. J Neuropathol Exp Neurol.2001,60(10):1004-1019.
[1]Young NS. Acquired aplastic anemia. Ann Intern Med.2002,136(7):534-546.
[2]Young NS, Calado RT, Scheinberg P. Current concepts in the pathophysiology and treatment of aplastic anemia. Blood.2006,108(8):2509-2519.
[3]Young NS, Bacigalupo A, Marsh JC. Aplastic anemia:pathophysiology and treatment. Biol Blood Marrow Transplant.2010,16(1 Suppl):S119-125.
[4]Rosenfeld S, Follmann D, Nunez O,et al. Antithymocyte globulin and cyclosporine for severe aplastic anemia: association between hematologic response and long-term outcome. JAMA.2003,289(9):1130-1135.
[5]Scheinberg P, Wu CO, Nunez O,et al. Predicting response to immunosuppressive therapy and survival in severe aplastic anaemia. Br J Haematol.2009,144(2):206-216.
[6]Gupta V,Carreras J,Bajorunaite R,et al.Hematopoietic recovery and over all survival after HLA-matched sibling transplants for older patients with severe aplastic anemia.Blood.2008,112:2169.
[7]Marsh JC, Ball SE, Cavenagh J, Darbyshire P,et al. Guidelines for the diagnosis and management of aplastic anaemia. Br J Haematol.2009,147(1):43-70.
[8]Deeg HJ, O'Donnell M, Tolar J,et al. Optimization of conditioning for marrow transplantation from unrelated donors for patients with aplastic anemia after failure of immunosuppressive therapy. Blood.2006,108(5):1485-1491.
[9]World Marrow Donor Association Donor Registries Working Group. Stem cell donor registries annual report 2008.12th ed.Leiden:World Marrow Donor Association;2008.
[10]Lee SJ, Klein J, Haagenson M, Baxter-Lowe LA,et al. High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation. Blood. 2007,110(13):4576-4583.
[11]Horowitz MM. High-resolution typing for unrelated donor transplantation: how far do we go? Best Pract Res Clin Haematol.2009,22(4):537-541.
[12]Perez-Albuerne ED, Eapen M, Klein J, Gross TJ,et al. Outcome of unrelated donor stem cell transplantation for children with severe aplastic anemia. Br J Haematol. 2008,141(2):216-223.
[13]Viollier R, Socie G, Tichelli A,et al. Recent improvement in outcome of unrelated donor transplantation for aplastic anemia. Bone Marrow Transplant.2008,41(1):45-50.
[14]Schrezenmeier H, Passweg JR, Marsh JC,et al. Worse outcome and more chronic GVHD with peripheral blood progenitor cells than bone marrow in HLA-matched sibling donor transplants for young patients with severe acquired aplastic anemia. Blood. 2007,110(4):1397-1400.
[15]Eapen M, Rubinstein P, Zhang MJ,et al. Outcomes of transplantation of unrelated donor umbilical cord blood and bone marrow in children with acute leukaemia:a comparison study. Lancet.2007,369(9577):1947-1954.
[16]Eapen M, Rocha V, Sanz Qet al. Effect of graft source on unrelated donor haemopoietic stem-cell transplantation in adults with acute leukaemia: a retrospective analysis. Lancet Oncol.2010,11(7):653-660.
[17]MacMillan ML, Walters MC, Gluckman E. Transplant outcomes in bone marrow failure syndromes and hemoglobinopathies. Semin Hematol.2010,47(l):37-45.
[18]Chan KW, McDonald L, Lim D,et al. Unrelated cord blood transplantation in children with idiopathic severe aplastic anemia. Bone Marrow Transplant.2008,42(9):589-595.
[19]Yoshimi A, Kojima S, Taniguchi S,et al. Unrelated cord blood transplantation for severe aplastic anemia. Biol Blood Marrow Transplant.2008,14(9):1057-1063.
[20]Margolis DA, Casper JT. Alternative-donor hematopoietic stem-cell transplantation for severe aplastic anemia. Semin Hematol.2000,37(l):43-55.
[21]Storb R, Anasetti C, Appelbaum F,et al. Marrow transplantation for severe aplastic anemia and thalassemia major. Semin Hematol.1991,28(3):235-239.
[22]Socie G, Henry-Amar M, Bacigalupo A,et al. Malignant tumors occurring after treatment of aplastic anemia. European Bone Marrow Transplantation-Severe Aplastic Anaemia Working Party. N Engl J Med.1993,329(16):1152-1157.
[23]Deeg HJ, Socie G, Schoch G,et al. Malignancies after marrow transplantation for aplastic anemia and fanconi anemia: a joint Seattle and Paris analysis of results in 700 patients. Blood.1996,87(1):386-392.
[24]Kojima S, Matsuyama T, Kato S,et al. Outcome of 154 patients with severe aplastic anemia who received transplants from unrelated donors:the Japan Marrow Donor Program. Blood.2002,100(3):799-803.
[25]Bacigalupo A, Locatelli F, Lanino E,et al. Fludarabine, cyclophosphamide and anti-thymocyte globulin for alternative donor transplants in acquired severe aplastic anemia: a report from the EBMT-SAA Working Party. Bone Marrow Transplant. 2005,36(11):947-950.
[26]Bacigalupo A, Socie' G, Lanino E,et al. Fludarabine, cyclophosphamide, antithymocyte globulin, with or without low dose total body irradiation, for alternative donor transplants, in acquired severe aplastic anemia: a retrospective study from the EBMT-SAA working party. Haematologica.2010,95(6):976-982.
[27]Fraser CJ, Bhatia S, Ness K,et al. Impact of chronic graft-versus-host disease on the health status of hematopoietic cell transplantation survivors:a report from the Bone Marrow Transplant Survivor Study. Blood.2006,108(8):2867-2873.
[28]Rizzo JD, Curtis RE, Socie Qet al. Solid cancers after allogeneic hematopoietic cell transplantation. Blood.2009,113(5):1175-1183.
© 2004-2018 中国地质图书馆版权所有 京ICP备05064691号 京公网安备11010802017129号 地址：北京市海淀区学院路29号 邮编：100083 电话：办公室：(+86 10)66554848；文献借阅、咨询服务、科技查新：66554700 |